Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-YL)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders
A novel crystalline free-plate habit of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid addresses filtration and stability issues, enhancing its effectiveness in treating S1P1 receptor-associated disorders by improving crystallinity and reducing hygroscopicity.
Patent Information
- Application Number
- CA3002551
- Authority / Receiving Office
- CA · CA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2015-08-20
- Filing Date
- 2016-06-21
- Publication Date
- 2026-11-03
- Estimated Expiration
- 2036-06-21
AI Technical Summary
Existing methods for preparing the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) do not adequately address issues of in-process filtration, formulation stability, and hygroscopicity, which are crucial for effective treatment of S1P1 receptor-associated disorders.
A novel crystalline free-plate habit of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid is prepared through specific processes involving hydrolysis with a lipase, salt formation with L-arginine, and controlled temperature and solvent cycling to enhance crystallinity and reduce hygroscopicity.
The novel crystalline free-plate habit exhibits improved filtration, stability, and reduced moisture absorption, enabling effective pharmaceutical formulations for treating S1P1 receptor-associated disorders such as multiple sclerosis and inflammatory conditions.
Abstract
Description
CRYSTALLINE L-ARGININE SALT OF (R)-2-(7-(4-CYCLOPENTYL-3- (TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLO-PENTA[B]INDOL-3- YL)ACETIC ACID (COMPOUND 1) FOR USE IN S1P1 RECEPTOR-ASSOCIATED DISORDERS FIELD OF THE INVENTION The present invention relates to, inter alia, a novel crystalline free-plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L- arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3- yl)acetic acid (Compound 1) in the treatment of S1P<com:Sub>1< / com:Sub> receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in the vascular integrity or that are associated with pathological angiogenesis (e.g., as may occur in inflammation, tumor development, and atherosclerosis). BACKGROUND OF THE INVENTION The sphingosine-1-phosphate (S1P) receptors 1-5 constitute a family of G protein-coupled receptors with a seven-transmembrane domain. These receptors, referred to as S1P<com:Sub>1< / com:Sub> to S1P<com:Sub>5< / com:Sub> (formerly termed endothelial differentiation gene (EDG) receptor-1, -5, -3, -6, and -8, respectively; Chun et. al., Pharmacological Reviews, 54:265-269, 2002), are activated via binding by sphingosine-1-phosphate, which is produced by the sphingosine kinase-catalyzed phosphorylation of sphingosine. S1P<com:Sub>1< / com:Sub>, S1P<com:Sub>4< / com:Sub>, and S1P<com:Sub>5< / com:Sub> receptors activate Gi but not Gq, whereas S1P<com:Sub>2< / com:Sub> and S1P<com:Sub>3< / com:Sub> receptors activate both Gi and Gq. The S1P<com:Sub>3< / com:Sub> receptor, but not the S1P<com:Sub>1< / com:Sub> receptor, responds to an agonist with an increase in intracellular calcium. The compound <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−(trifluoromethyl)benzyloxy)−1,2,3,4−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-< / annotation>< / semantics>< / com:Math> tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) is a potent (EC<com:Sub>50< / com:Sub> cAMP, 0.093 nM (human)) and selective (EC<com:Sub>50< / com:Sub> <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>-arrestin, 6.10 nM (S1P<com:Sub>1< / com:Sub>), >10,000 nM (S1P<com:Sub>2< / com:Sub>), >10,000 nM, (S1P<com:Sub>3< / com:Sub>), 147 nM (S1P<com:Sub>4< / com:Sub>), and 24.4 nM (S1P<com:Sub>5< / com:Sub>)), orally available investigational drug candidate for the S1P<com:Sub>1< / com:Sub> receptor. In preclinical studies, Compound 1 showed calculated lymphocyte lowering IC<com:Sub>50< / com:Sub> values in four different species: 0.101 µM (mouse), 0.051 µM (rat), 0.058 µM (dog), and 0.098 µM (monkey). Notably, the calculated lymphocyte lowering IC<com:Sub>50< / com:Sub> values reflect total plasma concentration wherein Compound 1 is highly protein bound (97.8% human, 98.0% rat). Compound 1 was shown to be efficacious in the murine experimental autoimmune encephalomyelitis (EAE) model that mimics multiple sclerosis. Prophylactically, Compound 1 prevented the onset and severity of disease relative to vehicle up to day 25, at which time dosing was discontinued. All treatment arms went on to develop severe disease. Therapeutic administration of Compound 1 was also examined. Treatment began at day 18, by which time all animals had developed severe disease. Compound 1 was administered from day 18 to day 37 and showed to reverse the disease relative to vehicle and was similar to the efficacy observed with fingolimod (i.e., GILENYA® was approved in September 2010 for the treatment of patients with relapsing forms of multiple sclerosis). Similarly, Compound 1 was efficacious in a collagen induced arthritis (CIA) model. Prophylactic oral administration in female Lewis rats resulted in a significant reduction in ankle diameters on day 17 following a daily oral dose and was similar to that observed in rats treated with fingolimod or methotrexate. Improvement in histological parameters in the knees and ankles of CIA rats was also observed, suggesting that inhibiting lymphocyte entry into arthritic joints with Compound 1 treatment suppresses CIA in rodents. Additional details can be found in the following, PCT application, serial number PCT / US2009 / 004265, filed 22 July 2009 (International Publication Number WO2010 / 011316); PCT application, serial number PCT / US2011 / 000153, filed 27 January 2011 (International Publication Number WO2011 / 094008); and Buzard: D. J., et. al., ACS Med. Chem. Lett. 2014, 5, 1313–1317. The L-arginine salt of Compound 1 was selected for clinical evaluation. A randomized, double- blind, placebo-controlled Phase 1b clinical trial was conducted to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of multiple-ascending doses of the L-arginine salt of Compound 1 in five different dosing cohorts. A total of 50 healthy volunteers received the L-arginine salt of Compound 1 and 10 healthy volunteers received placebo for 21 days. In the Phase 1b clinical trial, the administration of the L-arginine salt of Compound 1 demonstrated a dose-dependent effect on lymphocyte count lowering in blood, with a mean decrease from baseline of up to 69%. Lymphocyte counts, on average, recovered to baseline within one week of the conclusion of dosing. In view of the growing demand for compounds useful in the treatment of S1P<com:Sub>1< / com:Sub> receptor-associated disorders, the L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3-<com:Math><semantics>(trifluoromethyl)<annotation encoding="application / x-tex">(trifluoromethyl)< / annotation>< / semantics>< / com:Math>benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) has emerged as an important new compound. Accordingly, new and efficient methods are needed for the preparation of the L-arginine salt of Compound 1 and crystalline morphologies related thereto. Several improvements have now been discovered in this regard. These improvements are described herein. Citation of any reference throughout this application is not to be construed as an admission that such reference is prior art to the present application. SUMMARY OF THE INVENTION The present invention relates to, inter alia, a novel crystalline free-plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3-<com:Math><semantics>(trifluoromethyl)<annotation encoding="application / x-tex">(trifluoromethyl)< / annotation>< / semantics>< / com:Math>benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) in the treatment of S1P<com:Sub>1< / com:Sub> receptor- associated disorders, such as, those described herein. [Image disponible dans le document PDF, Image available in the PDF document] Discovery of the novel crystalline plate habit, referred to as "free-plate habit" herein, led to certain advantageous properties, such as, improved in-process filtrations, formulation stability and / or stability to degradation, higher degree of crystallinity, and lower degree of hygroscopicity, see Example 8 for details. Certain processes for the preparation of the L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid have been previously described; see WO2010 / 011316 and WO2011 / 094008. One aspect of the present invention relates to methods for preparing a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid, the method comprising the steps of: a) hydrolyzing a compound of Formula (IIa): [Image disponible dans le document PDF, Image available in the PDF document] wherein R<com:Sup>3< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; in the presence of a hydrolyzing mixture comprising a lipase and a hydrolyzing-step solvent to form <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3-<com:Math><semantics>(trifluoromethyl)<annotation encoding="application / x-tex">(trifluoromethyl)< / annotation>< / semantics>< / com:Math>benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid; b) adding L-arginine to a salt-forming mixture comprising <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, a water-miscible anti-solvent, and H<com:Sub>2< / com:Sub>O to form a first mixture comprising L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; c) heating the first mixture to a first heating temperature; d) adding a first additional amount of the water-miscible anti-solvent to the first mixture to form a suspension; and e) cooling the suspension to form the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>- 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. One aspect of the present invention relates to methods for preparing a crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−(trifluoromethyl)benzyloxy)−1,2,3,4−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-< / annotation>< / semantics>< / com:Math> tetrahydrocyclopenta[b]indol-3-yl)acetic acid, said method comprising the steps of: a) hydrolyzing a compound of Formula (IIa): [Image disponible dans le document PDF, Image available in the PDF document] wherein R<com:Sup>3< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; in the presence of a hydrolyzing mixture comprising a lipase and a hydrolyzing-step solvent to form (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid; b) forming a first mixture comprising L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, a water-miscible anti-solvent, and H<com:Sub>2< / com:Sub>O; c) heating the first mixture to a first heating temperature to form a second mixture; d) adding a first additional amount of said water-miscible anti-solvent to said second mixture while maintaining said first heating temperature to form a suspension; e) cooling said suspension to a first cooling temperature and thereafter heating to a second heating temperature; f) cycling Step e) optionally one or more times, wherein said first cooling temperature at each cycle may be the same or different and said second heating temperature at each cycle may be the same or different; and g) cooling said suspension to a final cooling temperature to form said crystalline free- plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid. One aspect of the present invention relates to methods for preparing a crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−(trifluoromethyl)benzyloxy)−1,2,3,4−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-< / annotation>< / semantics>< / com:Math> tetrahydrocyclopenta[b]indol-3-yl)acetic acid, the method comprising the steps of: a) adding L-arginine to a salt-forming mixture comprising <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, a water-miscible anti-solvent, and H<com:Sub>2< / com:Sub>O to form a first mixture comprising L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; b) heating the first mixture to a first temperature; c) adding a first additional amount of the water-miscible anti-solvent to the first mixture to form a suspension; and d) cooling the suspension to form the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>- 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. One aspect of the present invention relates to methods for preparing a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid, the method comprising the steps of: a) heating a first mixture comprising L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, a water-miscible anti-solvent, and water to a first heating temperature to form a second mixture; b) cooling the second mixture to a first cooling temperature followed by adding a first additional amount of the water-miscible anti-solvent to the second mixture while maintaining the first cooling temperature and thereafter heating to a second heating temperature to form a suspension; C) cycling Step b) optionally once or twice; and d) cooling the suspension to a second cooling temperature to form the crystalline free- plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid. One aspect of the present invention relates to methods for preparing a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid, said method comprising the steps of: a) forming a first mixture comprising L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, a water-miscible anti-solvent, and H<com:Sub>2< / com:Sub>O; b) heating the first mixture to a first heating temperature to form a second mixture; c) adding a first additional amount of said water-miscible anti-solvent to said second mixture while maintaining said first heating temperature to form a suspension; d) cooling the suspension to a first cooling temperature and thereafter heating to a second heating temperature; e) cycling Step d) optionally one or more times, wherein the first cooling temperature at each cycle may be the same or different and the second heating temperature at each cycle may be the same or different; and f) cooling said suspension to a final cooling temperature to form said crystalline free- plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid. One aspect of the present invention relates to methods for preparing a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid further comprising the step of formulating the crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid to form a pharmaceutical composition. One aspect of the present invention relates to methods for preparing a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid further comprising the step of admixing the crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid with a pharmaceutical excipient to form a pharmaceutical composition. One aspect of the present invention relates to pharmaceutical compositions prepared according to any of the methods described herein. One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid prepared according to any of the methods described herein. One aspect of the present invention relates to compositions comprising a crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−(trifluoromethyl)benzyloxy)−1,2,3,4−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-< / annotation>< / semantics>< / com:Math> tetrahydrocyclo-penta[b]indol-3-yl)acetic acid prepared according to any of the methods described herein. One aspect of the present invention relates to pharmaceutical compositions comprising a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)- 1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid prepared according to any of the methods described herein and a pharmaceutical excipient. One aspect of the present invention relates to pharmaceutical compositions comprising a crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3-<com:Math><semantics>(trifluoromethyl)<annotation encoding="application / x-tex">(trifluoromethyl)< / annotation>< / semantics>< / com:Math>benzyloxy)- 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) in an amount equivalent to a therapeutically effective amount of Compound 1 of the crystalline free-plate habit, wherein the pharmaceutical composition further comprises a diluent, a disintegrant, and a lubricant. One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid having a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±<annotation encoding="application / x-tex">16.4^{\circ} \pm< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2∘<annotation encoding="application / x-tex">0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid having a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.0°C to 208.5°C when scanned at 10°C per minute. One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid having a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.3% weight or less at 90% RH. One aspect of the present invention relates to compositions comprising a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclo-penta[b]indol-3-yl)acetic acid as described herein. One aspect of the present invention relates to pharmaceutical compositions comprising a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)- 1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid as described herein and a pharmaceutical excipient. One aspect of the present invention relates to methods for treating an S1P<com:Sub>1< / com:Sub> receptor-associated disorder in an individual comprising administering to the individual in need thereof a therapeutically effective amount of a crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid as described herein, a composition as described herein, or a pharmaceutical composition as described herein. One aspect of the present invention relates to uses of a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)acetic acid as described herein in the manufacture of a medicament for the treatment of an S1P<com:Sub>1< / com:Sub> receptor-associated disorder. One aspect of the present invention relates to uses of a composition comprising a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid as described herein and an excipient in the manufacture of a medicament for administration in the treatment of an S1P<com:Sub>1< / com:Sub> receptor-associated disorder. One aspect of the present invention relates to uses of a composition comprising a crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3-<com:Math><semantics>(trifluoromethyl)<annotation encoding="application / x-tex">(trifluoromethyl)< / annotation>< / semantics>< / com:Math>benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid as described herein and an excipient for preparation a medicament for administration in the treatment of an S1P<com:Sub>1< / com:Sub> receptor-associated disorder. One aspect of the present invention relates to uses of a composition comprising a crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3-<com:Math><semantics>(trifluoromethyl)<annotation encoding="application / x-tex">(trifluoromethyl)< / annotation>< / semantics>< / com:Math>benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid as described herein and an excipient for compounding a medicament for administration in the treatment of an S1P<com:Sub>1< / com:Sub> receptor-associated disorder. One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid as described herein for use in a method for the treatment of the human or animal body by therapy. One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid as described herein for use in a method for the treatment of an S1P<com:Sub>1< / com:Sub> receptor-associated disorder. In some embodiments, the S1P<com:Sub>1< / com:Sub> receptor-associated disorder is selected from: primary biliary cirrhosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, multiple sclerosis, inflammatory bowel disease, systemic lupus erythematosus, and ulcerative colitis. One aspect of the present invention relates to a method for preparing a crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3-<com:Math><semantics>(trifluoromethyl)<annotation encoding="application / x-tex">(trifluoromethyl)< / annotation>< / semantics>< / com:Math>benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid, said method comprising the steps of: a) forming a first mixture comprising L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid, a water-miscible anti-solvent, and H<com:Sub>2< / com:Sub>O; b) heating the first mixture to a first heating temperature to form a second mixture; wherein said first heating temperature is about 79°C to about 85°C; c) adding a first additional amount of said water-miscible anti-solvent to said second mixture while maintaining said first heating temperature to form a suspension; d) cooling the suspension to a first cooling temperature and thereafter heating to a second heating temperature; wherein said first cooling temperature is about 18°C to about 22°C, and said second heating temperature is about 69°C to about 73°C; e) cycling Step d) optionally one or more times, wherein the first cooling temperature at each cycle may be the same or different and the second heating temperature at each cycle may be the same or different; and f) cooling said suspension to a final cooling temperature to form said crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4- cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; wherein said final cooling temperature is about 18°C to about 22°C. One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2- (7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; wherein said crystalline free-plate habit has a BET specific surface area of about 0.1 m<com:Sup>2< / com:Sup> / g to about 5.0 m<com:Sup>2< / com:Sup> / g. One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; wherein the crystalline free-plate habit is characterised by hexagonal-like plates with two opposite sides of the plate being longer than the other sides; wherein the crystalline free-plate habit comprises complete plates, substantially complete plates, fragments / broken pieces of plates, and mixtures thereof that are free or substantially free of radial clusters or spherulites; and wherein radial clusters and spherulites are a crystal habit consisting of plates or flakes that are clustered in a radial manner around a nucleation site. One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; wherein the crystalline free-plate habit is characterised by hexagonal-like plates with two opposite sides of the plate being longer than the other sides as measured by microscopy; wherein the crystalline free-plate habit is free of radial clusters or spherulites; and wherein radial clusters and spherulites are a crystal habit consisting of plates or flakes that are clustered in a radial manner around a nucleation site. One aspect of the present invention relates to L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid in the form of a crystalline free-plate habit substantially free of radial clusters or spherulites. One aspect of the present invention relates to L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid in the form of a crystalline free-plate habit containing a total amount of compound A and compound B that is less than 0.9% after storage for six months at 40°C / 75% RH, wherein compound A and compound B have the following formulae: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] One aspect of the present invention relates to L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid in the form of a crystalline free-plate habit having a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.3% weight or less at 90% RH. One aspect of the present invention relates to L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid in the form of a crystalline free-plate habit having a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.0°C to 208.5°C at a scan rate of 10°C / minute. These and other aspects of the invention disclosed herein will be set forth in greater detail as the patent disclosure proceeds. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows a micrograph of spherulites / radial clusters using scanning electron microscopy (SEM), see Example 1 for additional details. Figure 2 shows a micrograph of spherulites / radial clusters using polarized light microscopy (PLM), see Example 1 for additional details. Figure 3A shows a micrograph of the crystal morphology as described in Example 2 (Lot J2) using scanning electron microscopy (SEM). Figure 3B shows a micrograph of the crystal morphology as described in Example 2 (Lot J2). Figure 4A shows a micrograph of the crystal morphology as described in Example 2 (Lot J1) using scanning electron microscopy (SEM). Figure 4B shows a micrograph of the crystal morphology as described in Example 2 (Lot J1). Figure 5A shows a micrograph of the crystal plate morphology as described in Example 3 using polarized light microscopy (PLM). Figure 5B shows the same micrograph as in Figure 5A of the crystal plate morphology as described in Example 3 using polarized light microscopy (PLM) but also includes an added outline of a substantially intact / complete free-plate having an elongated hexagonal shape. Figure 6 shows a differential scanning calorimetry (DSC) thermogram for Lot A1 (plates) as described in Example 3. Figure 7 shows a differential scanning calorimetry (DSC) thermogram for Lot A2 (plates) as described in Example 3. Figure 8 shows a differential scanning calorimetry (DSC) thermogram for Lot A3 (plates) as described in Example 3. Figure 9 shows a differential scanning calorimetry (DSC) thermogram for Lot A4 (plates) as described in Example 3. Figure 10 shows a differential scanning calorimetry (DSC) thermogram for Lot A5 (plates) as described in Example 3. Figure 11 shows a micrograph of the crystal plate morphology as described in Example 4.1, Method 1 using polarized light microscopy (PLM). Figure 12A shows a micrograph of the crystal plate morphology as described in Example 4.1, Method 1 using polarized light microscopy (PLM). Figure 12B shows a differential scanning calorimetry (DSC) thermogram for a sample from Example 4.1, Method 1 (plates). Figure 13 shows a PXRD pattern overlay for Lot A5 and the sample from Example 4.2, Method 2 showing that the sample has the same crystal phase as the Lot A5 (plates). Figure 14 shows a micrograph for a sample from Example 4.2, Method 2 using polarized light microscopy (PLM). It was observed that the sample consisted predominately as plates. Figure 15 shows a flowchart for the preparation of core tablets of the L-arginine salt of (R)-2- (7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1). Figure 16 shows an adsorption phase and a desorption phase from a dynamic moisture-sorption (DMS) analysis for a representative lot having plate morphology (i.e., Lot A2). Figure 17 shows an adsorption / desorption cycle for a representative lot having plate morphology (i.e., Lot A2). Figure 18 shows a PXRD pattern overlay for five lots (i.e., A1 to A5, plates) of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3- yl)acetic acid (Compound 1). See Example 3 for additional details. Figure 19 shows a PXRD Pattern overlay for the L-arginine salt of Compound 1 showing the peak intensity differences between Lot A2 (plates) and Lot H2 (spherulites) indicating a higher degree of crystallinity for the plates compared to the spherulites. Also shown is the lower sample-related background scatter (i.e., a lower amorphous halo contribution) for the Lot A2 (plates). Figure 20 shows a micrograph for a crystalline sample from Example 7, Method 1 Step B (WO2011 / 094008) using polarized light microscopy (PLM). The sample was observed to have uniform radial cluster (spherulite) shaped particles with a few fine particles. Figure 21 shows a purification flow chart, see Example 8 for additional details. Figure 22 shows a differential scanning calorimetry (DSC) thermogram for Lot A6 (plates) as described in Example 3. Figure 23 shows a differential scanning calorimetry (DSC) thermogram for Lot A7 (plates) as described in Example 3. Figure 24 shows a differential scanning calorimetry (DSC) thermogram for Lot A8 (plates) as described in Example 3. Figure 25 shows a differential scanning calorimetry (DSC) thermogram for Lot A9 (plates) as described in Example 3. DETAILED DESCRIPTION OF THE INVENTION DEFINITIONS For clarity and consistency, the following definitions will be used throughout this patent document. The phrase "L-arginine salt of Compound 1" refers to the L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−<annotation encoding="application / x-tex">(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid: [Image disponible dans le document PDF, Image available in the PDF document] The phrase "as depicted in" with reference to a Figure refers to the crystal form and / or morphology as being characterized by graphical data "as depicted in" the Figure. Such data include, for example, powder X-ray diffractograms, differential scanning calorimetry traces, and dynamic moisture sorption graphs. The skilled person will understand that such graphical representations of data may be subject to small variations, e.g., in peak relative intensities and peak positions due to factors such as variations in instrument response and variations in sample concentration and purity, which are well known to the skilled person. Nonetheless, the skilled person would readily be capable of comparing the graphical data in the Figures herein with graphical data generated for an unknown crystal form and / or morphology (habit) and confirm whether the two sets of graphical data are characterizing the same crystal form (or morphology) or two different crystal forms (or morphologies). A crystalline free-plate habit of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)-benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) referred to herein as being characterized by graphical data "as depicted in" a Figure will thus be understood to include any morphologies characterized with the graphical data having such small variations, as are well known to the skilled person, in comparison with the Figure. The term "composition" refers to a compound or salt thereof, such as, L-arginine salt of (R)-2- (7-(4-cyclopentyl-3-(trifluoromethyl)-benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, in combination with at least one additional component. The term "formulating" as used herein refers to the step(s) to transform the bulk active pharmaceutical agent (i.e., API) into the drug substance or drug product for use in an individual for the treatment of a disease, wherein "treatment" and "individual" has the same definitions as described herein. The phrase "free-plate habit" refers to the general shape of an independent substantially flat crystal with a length and width of the crystal being similar and substantially greater than the thickness and wherein the plate is not part of a radial cluster such as a spherulite. It is appreciated that due to the thin characteristic of the crystals, the phrase "free-plate habit" encompasses complete plates, substantially complete plates, fragments / broken pieces of plates, and mixtures thereof that are free or substantially free of radial clusters or spherulites. The term "spherulite" and "radial cluster" refers to a crystal habit consisting of thin plates or flakes that are clustered in a radial manner around a nucleation site that exhibit a cross when viewed using crossed-polarized light, see Figure 1 and Figure 2 for micrographs of representative spherulites / radial clusters. Typically the length of the thin plates making up the radial cluster is less than 10µm. The term "length" in the context of a crystalline habit refers to the longest dimension from edge to edge of a particle oriented parallel to the ocular scale. The term "width" in the context of a crystalline habit refers to the longest dimension of the particle measured at right angles to the length. The term "individual" as used herein refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates and most preferably humans. The term "inert atmosphere" as used herein refers to an atmosphere substantially free of oxygen. Examples of an inert atmosphere include, for example, argon and nitrogen. The term "pharmaceutical composition" as used herein refers to a composition comprising at least one active ingredient; such as Compound 1 and the L-arginine salt thereof, whereby the composition is amenable to investigation for a specified pharmacological outcome in a mammal (for example, without limitation, a human) or the treatment of a disease or disorder as described herein. Those of ordinary skill in the art will understand and appreciate the techniques appropriate for determining whether an active ingredient has a desired efficacious outcome based upon the needs of the artisan. The term "treatment" or "treating" as used herein includes one or more of the following: (1) prevention of a disease, for example, prevention of a disease, condition or disorder in an individual that may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease; (2) inhibition of a disease, for example, inhibition of a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and / or symptomatology); and (3) amelioration of a disease, for example, amelioration of a disease, condition or disorder in an individual that is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and / or symptomatology). Whether an individual is in need of treatment is a judgment made by a caregiver (e.g. nurse practitioner, physician, physician assistant, nurse, etc. in the case of humans; veterinarian in the case of animals, including non-human mammals) that an individual or animal requires or will benefit from treatment. This judgment is made based on a variety of factors that are in the realm of a caregiver's expertise, but that includes the knowledge that the individual or animal is ill, or will become ill, as the result of a disease, condition or disorder that is treatable by Compound 1 or a pharmaceutically acceptable salt, solvate, and hydrate thereof, such as, the L-arginine salt of Compound 1. Accordingly, Compound 1 and / or pharmaceutically acceptable salts, solvates and hydrates thereof, such as, the L- arginine salt of Compound 1, can be used in a protective or preventive manner; or Compound 1 and pharmaceutically acceptable salts, solvates and hydrates thereof, such as, the L-arginine salt of Compound 1, can be used to alleviate, inhibit, or ameliorate a disease, condition, or disorder. The phrase "water-miscible anti-solvent" as used herein refers to a water soluble solvent in which the product, such as the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)- benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, has limited solubility. CHEMICAL GROUP, MOIETY OR RADICAL The term "C<com:Sub>2< / com:Sub>-C<com:Sub>4< / com:Sub> alkanol" refers to a straight or branched carbon radical containing 2 to 4 carbons bonded to an -OH group. Some embodiments are 2 to 3 carbons and some embodiments are 3 to 4 carbons. Examples of a <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkanol include, but are not limited to, ethanol, 1-propanol, 2- propanol, 1-butanol, 2-butanol, and the like. The term "C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl" refers to a straight or branched carbon radical containing 1 to 6 carbons. Some embodiments are 1 to 5 carbons, some embodiments are 1 to 4 carbons, some embodiments are 1 to 3 carbons and some embodiments are 1 or 2 carbons. Examples of an alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, isopentyl, tert-pentyl, neo-pentyl, 1-methylbutyl [i.e., CH(CH<com:Sub>3< / com:Sub>)CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>], 2-methylbutyl [i.e., CH<com:Sub>2< / com:Sub>CH(CH<com:Sub>3< / com:Sub>)CH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>], n-hexyl and the like. It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. In addition, subcombinations of uses and medical indications listed in the embodiments describing such uses and medical indications described herein, are also specifically embraced by the present invention just as if each and every subcombination of uses and medical indications was individually and explicitly recited herein. CERTAIN METHODS OF THE INVENTION Described herein are methods for preparing the crystalline plate morphology of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3- yl)acetic acid using an enzymatic hydrolysis of the corresponding <com:Math><semantics>(R / S)<annotation encoding="application / x-tex">(R / S)< / annotation>< / semantics>< / com:Math>-ethyl ester to the <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-acid followed by a modified L-arginine salt-forming procedure compared to what was previously disclosed in WO2011 / 094008 and isolating the L-arginine salt of Compound 1 as the crystalline free-plate habit or morphology. Accordingly, one aspect of the present invention relates to methods for preparing a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid, the method comprising the steps of: a) hydrolyzing a compound of Formula (IIa): [Image disponible dans le document PDF, Image available in the PDF document] wherein R<com:Sup>3< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; in the presence of a hydrolyzing mixture comprising a lipase and a hydrolyzing-step solvent to form (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid; b) adding L-arginine to a salt-forming mixture comprising <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, a water-miscible anti-solvent, and H<com:Sub>2< / com:Sub>O to form a first mixture comprising L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; c) heating the first mixture to a first heating temperature; d) adding a first additional amount of the water-miscible anti-solvent to the first mixture to form a suspension; and e) cooling the suspension to form the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>- 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. In some embodiments, the method for preparing a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)acetic acid is conducted under an inert atmosphere. In some embodiments, the method is conducted under an inert atmosphere comprising nitrogen or argon. In some embodiments, the method is conducted under an inert atmosphere comprising nitrogen. Step a) - Hydrolyzing a Compound of Formula (IIa). In some embodiments, the hydrolyzing in Step a) is conducted under an inert atmosphere. In some embodiments, the hydrolyzing in Step a) is conducted under an inert atmosphere comprising nitrogen or argon. In some embodiments, the hydrolyzing in Step a) is conducted under an inert atmosphere comprising nitrogen. In some embodiments, <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math> is methyl or ethyl. In some embodiments, <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math> is ethyl. In some embodiments, the lipase is Candida antarctica lipase B. In some embodiments, the lipase is immobilized Candida antarctica lipase B. In some embodiments, the hydrolyzing-step solvent comprises dimethylformamide (DMF), dimethylacetamide (DMA), dimethylsulfoxide (DMSO), tetrahydrofuran (THF), or acetonitrile. In some embodiments, the hydrolyzing-step solvent comprises acetonitrile. In some embodiments, the compound of Formula (IIa) is: [Image disponible dans le document PDF, Image available in the PDF document] the lipase is immobilized Candida antarctica lipase B; and the hydrolyzing-step solvent comprises acetonitrile. In some embodiments, the hydrolyzing in Step a) is conducted in the presence of a phosphate buffer. In some embodiments, the hydrolyzing in Step a) is conducted in the presence of a phosphate buffer at a pH of about 6.0 to about 9.0. In some embodiments, the hydrolyzing in Step a) is conducted in the presence of a phosphate buffer at a pH of about 7.0 to about 8.5. In some embodiments, the hydrolyzing in Step a) is conducted in the presence of a phosphate buffer at a pH of about 7.3 to about 8.3. In some embodiments, the hydrolyzing in Step a) is conducted in the presence of a phosphate buffer at a pH of about 7.6 to about 8.0. In some embodiments, the hydrolyzing in Step a) is conducted in the presence of a phosphate buffer at a pH of about 7.8. In some embodiments, the phosphate buffer is a sodium phosphate buffer. In some embodiments, the phosphate buffer is a potassium phosphate buffer. In some embodiments, the hydrolyzing in Step a) is conducted at a temperature of about 0°C to about 75°C. In some embodiments, the hydrolyzing in Step a) is conducted at a temperature of about 20°C to about 65°C. In some embodiments, the hydrolyzing in Step a) is conducted at a temperature of about 30°C to about 55°C. In some embodiments, the hydrolyzing in Step a) is conducted at a temperature of about 35°C to about 45°C. In some embodiments, the hydrolyzing in Step a) further comprises the step of isolating the (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. In some embodiments, after isolating, the <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−(trifluoromethyl)−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)-< / annotation>< / semantics>< / com:Math> benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has an enantiomeric excess of about 95% or greater. In some embodiments, after isolating, the (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)- benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has an enantiomeric excess of about 98% or greater. In some embodiments, after isolating, the (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)- benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has an enantiomeric excess of about 99% or greater. Step b) - Adding L-Arginine to a Salt-Forming Mixture. In some embodiments, the adding in Step b) is conducted under an inert atmosphere. In some embodiments, the adding in Step b) is conducted under an inert atmosphere comprising argon or nitrogen. In some embodiments, the adding in Step b) is conducted under an inert atmosphere comprising nitrogen. In some embodiments, the water-miscible anti-solvent in Step b) comprises a solvent selected from the group consisting of: acetonitrile, acetone, tetrahydrofuran, and <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkanol. In some embodiments, the water-miscible anti-solvent in Step b) comprises a solvent selected from the group consisting of: acetonitrile, acetone, tetrahydrofuran, ethanol, 1-propanol, 2-propanol, and 1-butanol. In some embodiments, the water-miscible anti-solvent in Step b) comprises 2-propanol. In some embodiments, the molar ratio between (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L-arginine is about 1.0:0.95 to about 1.0:1.2. In some embodiments, the molar ratio between <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-< / annotation>< / semantics>< / com:Math> 3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L-arginine is about 1.0:1.0 to about 1.0:1.2. In some embodiments, the molar ratio between <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-< / annotation>< / semantics>< / com:Math> 3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L-arginine is about 1.0:1.0. In some embodiments, the salt-forming mixture prior to the adding L-arginine is at a temperature of about 15°C to about 83°C. In some embodiments, the salt-forming mixture prior to the adding L-arginine is at a temperature of about 18°C to about 80°C. In some embodiments, the salt- forming mixture prior to the adding L-arginine is at a temperature of about 20°C to about 40°C. One aspect of the present invention allows for the L-arginine to be added to the salt-forming mixture as a solid. In some embodiments, the adding L-arginine in Step b) is conducted by adding L-arginine as a solid to the salt-forming mixture. In some embodiments, the adding L-arginine in Step b) is conducted by adding L-arginine as a solid to the salt-forming mixture substantially all at once. The phrase "substantially all at once" or "all at once" refers to the addition of all of the L-arginine to the salt-forming mixture at one time with the only limitation that is placed on the addition is by any limitation associated with the equipment used. In some embodiments, the adding L-arginine in Step b) is conducted by adding L-arginine as a solid to the salt-forming mixture over a period of 30 minutes. In some embodiments, the adding L- arginine in Step b) is conducted by adding L-arginine as a solid to the salt-forming mixture over a period of 1 hour. In some embodiments, the adding L-arginine in Step b) is conducted by adding L- arginine as a solid to the salt-forming mixture over a period of 2 hours. In some embodiments, the salt-forming mixture comprises <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.00:4.98:0.94 to about 1.00:7.46:1.40. In some embodiments, the salt- forming mixture comprises (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro- cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.00:5.29:0.99 to about 1.00:7.15:1.35. In some embodiments, the salt-forming mixture comprises <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−<annotation encoding="application / x-tex">(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid, 2- propanol, and water in a weight ratio of about 1.00:5.60:1.05 to about 1.00:6.84:1.29. In some embodiments, the salt-forming mixture comprises (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.00:5.72:1.08 to about 1.00:6.72:1.26. In some embodiments, the salt- forming mixture comprises (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro- cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.00:5.85:1.10 to about 1.00:6.59:1.24. In some embodiments, the salt-forming mixture comprises (R)-2-(7-(4- cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid, 2- propanol, and water in a weight ratio of about 1.00:5.97:1.12 to about 1.00:6.47:1.22. In some embodiments, the salt-forming mixture comprises <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.00:6.10:1.15 to about 1.00:6.34:1.19. In some embodiments, the salt- forming mixture comprises (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro- cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.00:6.22:1.17. In some embodiments, the salt-forming mixture during the adding L-arginine is at a temperature of about 15°C to about 83°C. In some embodiments, the salt-forming mixture during the adding L-arginine is at a temperature of about 18°C to about 80°C. In some embodiments, the salt- forming mixture during the adding L-arginine is at a temperature of about 20°C to about 40°C. One aspect of the present invention allows for the L-arginine to be added to the salt-forming mixture as an aqueous solution. In some embodiments, the adding L-arginine in Step b) is conducted by adding L-arginine as an aqueous solution to the salt-forming mixture. In some embodiments, the adding L-arginine in Step b) is conducted by adding L-arginine to the salt-forming mixture wherein L-arginine is a solution of about 2.1M to about 2.3M aqueous solution at a temperature of about 50°C to about 75°C. In some embodiments, the adding L-arginine in Step b) is conducted by adding L-arginine to the salt-forming mixture wherein L-arginine is a solution of about 2.26 M to about 2.28 M aqueous solution at a temperature of about 55°C to about 65°C. In some embodiments, after adding L-arginine as an aqueous solution in Step b) the weight ratio of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3- yl)acetic acid, 2-propanol, and <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math> is about 1.00:4.98:0.94 to about 1.00:7.46:1.40. In some embodiments, after adding L-arginine as an aqueous solution in Step b) the weight ratio of <com:Math><semantics>(R)−2−(7−(4−<annotation encoding="application / x-tex">(R)-2-(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid, 2- propanol, and H<com:Sub>2< / com:Sub>O is about 1.00:5.29:0.99 to about 1.00:7.15:1.35. In some embodiments, after adding L-arginine as an aqueous solution in Step b) the weight ratio of (R)-2-(7-(4-cyclopentyl-3-(trifluoro- methyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and H<com:Sub>2< / com:Sub>O is about 1.00:5.60:1.05 to about 1.00:6.84:1.29. In some embodiments, after adding L-arginine as an aqueous solution in Step b) the weight ratio of <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−(trifluoromethyl)benzyloxy)−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-< / annotation>< / semantics>< / com:Math> 1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and H<com:Sub>2< / com:Sub>O is about 1.00:5.72:1.08 to about 1.00:6.72:1.26. In some embodiments, after adding L-arginine as an aqueous solution in Step b) the weight ratio of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−(trifluoromethyl)benzyloxy)−1,2,3,4−tetrahydro−cyclo−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclo-< / annotation>< / semantics>< / com:Math> penta[b]indol-3-yl)acetic acid, 2-propanol, and H<com:Sub>2< / com:Sub>O is about 1.00:5.85:1.10 to about 1.00:6.59:1.24. In some embodiments, after adding L-arginine as an aqueous solution in Step b) the weight ratio of (R)-2- (7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math> is about 1.00:5.97:1.12 to about 1.00:6.47:1.22. In some embodiments, after adding L-arginine as an aqueous solution in Step b) the weight ratio of <com:Math><semantics>(R)−2−(7−(4−cyclopenty)−3−(4−cyclopenty))<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopenty)-3-(4-cyclopenty))< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and H<com:Sub>2< / com:Sub>O is about 1.00:6.10:1.15 to about 1.00:6.34:1.19. In some embodiments, after adding L-arginine as an aqueous solution in Step b) the weight ratio of <com:Math><semantics>(R)−2−(7−(4−cyclopenty)−3−(trifluoromethy)benzyl−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopenty)-3-(trifluoromethy)benzyl-< / annotation>< / semantics>< / com:Math> oxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and H<com:Sub>2< / com:Sub>O is about 1.00:6.22:1.17. In some embodiments, Step b) is conducted at a stir rate of about 100 rpm to about 200 rpm. In some embodiments, Step b) is conducted at a stir rate of about 125 rpm to about 175 rpm. In some embodiments, Step b) is conducted at a stir rate of about 150 rpm. Step c) - Heating the First Mixture to a First Heating Temperature. In some embodiments, the first heating temperature is about 20°C to about 83°C. In some embodiments, the first heating temperature is about 20°C to about 55°C. In some embodiments, the first heating temperature is about 25°C to about 45°C. In some embodiments, the first heating temperature is about 50°C to about 83°C. In some embodiments, the first heating temperature is about 60°C to about 80°C. In some embodiments, the first heating temperature is about 70°C to about 80°C. In some embodiments, the first mixture is substantially a homogeneous solution. In some embodiments, Step c) is conducted at a stir rate of about 100 rpm to about 200 rpm. In some embodiments, Step c) is conducted at a stir rate of about 125 rpm to about 175 rpm. In some embodiments, Step c) is conducted at a stir rate of about 150 rpm. Step d) - Adding a First Additional Amount of the Water-Miscible Anti-Solvent to the First Mixture to Form a Suspension. In some embodiments, the water-miscible anti-solvent in Step b) comprises a solvent selected from the group consisting of: acetonitrile, acetone, tetrahydrofuran, and <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkanol. In some embodiments, the water-miscible anti-solvent in Step b) comprises a solvent selected from the group consisting of: acetonitrile, acetone, tetrahydrofuran, ethanol, 1-propanol, 2-propanol, and 1-butanol. In some embodiments, the water-miscible anti-solvent in Step b) comprises 2-propanol. In some embodiments, the weight ratio of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:5.46 to about 1.00:8.20. In some embodiments, the weight ratio of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:5.81 to about 1.00:7.86. In some embodiments, the weight ratio of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−<annotation encoding="application / x-tex">(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:6.15 to about 1.00:7.51. In some embodiments, the weight ratio of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−(trifluoromethyl)benzyloxy)−1,2,3,4−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-< / annotation>< / semantics>< / com:Math> tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:6.28 to about 1.00:7.38. In some embodiments, the weight ratio of L-arginine salt of (R)-2-(7-(4- cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:6.42 to about 1.00:7.24. In some embodiments, the weight ratio of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:6.56 to about 1.00:7.10. In some embodiments, the weight ratio of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−<annotation encoding="application / x-tex">(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:6.69 to about 1.00:6.97. In some embodiments, the weight ratio of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−(trifluoromethyl)benzyloxy)−1,2,3,4−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-< / annotation>< / semantics>< / com:Math> tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:6.83. In some embodiments, adding the first additional amount of 2-propanol to the first mixture is conducted at a rate to complete the addition in about 5.00 hours to about 10.00 hours. In some embodiments, adding the first additional amount of 2-propanol to the first mixture is conducted at a rate to complete the addition in about 6.75 hours to about 8.25 hours. In some embodiments, adding the first additional amount of 2-propanol to the first mixture is conducted at a rate to complete the addition in about 6.90 hours to about 8.10 hours. In some embodiments, adding the first additional amount of 2- propanol to the first mixture is conducted at a rate to complete the addition in about 7.05 hour to about 7.95 hour. In some embodiments, adding the first additional amount of 2-propanol to the first mixture is conducted at a rate to complete the addition in about 7.20 hours to about 7.80 hours. In some embodiments, adding the first additional amount of 2-propanol to the first mixture is conducted at a rate to complete the addition in about 7.35 hours to about 7.65 hours. In some embodiments, adding the first additional amount of 2-propanol to the first mixture is conducted at a rate to complete the addition in about 7.50 hours. In some embodiments, the first heating temperature is maintained during adding the first additional amount of 2-propanol to the first mixture. In some embodiments, after adding the first additional amount of 2-propanol to the first mixture in Step c), the method further comprises forming a second mixture while maintaining the first heating temperature, wherein the second mixture is formed prior to forming the suspension. In some embodiments, the method further comprises cooling the second mixture to a first cooling temperature followed by heating to a second heating temperature to form the suspension. In some embodiments, cooling the second mixture to the first cooling temperature is conducted at a rate of about 8.80°C / hour to about 14.40°C / hour. In some embodiments, cooling the second mixture to the first cooling temperature is conducted at a rate of about 9.35°C / hour to about 13.80°C / hour. In some embodiments, cooling the second mixture to the first cooling temperature is conducted at a rate of about 9.90°C / hour to about 13.20°C / hour. In some embodiments, cooling the second mixture to the first cooling temperature is conducted at a rate of about 10.45°C / hour to about 12.60°C / hour. In some embodiments, cooling the second mixture to the first cooling temperature is conducted at a rate of about 10°C / hour to about 12°C / hour. In some embodiments, the first cooling temperature is about 15°C to about 40°C. In some embodiments, the first cooling temperature is about 20°C to about 30°C. In some embodiments, the first cooling temperature is about 22°C to about 24°C. In some embodiments, the first cooling temperature is maintained for at least 1 hour prior to heating to the second heating temperature. In some embodiments, the second heating temperature is about 65°C to about 83°C. In some embodiments, the second heating temperature is about 70°C to about 80°C. In some embodiments, the second heating temperature is about 70°C to about 75°C. In some embodiments, after heating to the second heating temperature, the second heating temperature is maintained for at least 30 minutes. In some embodiments, Step d) is conducted at a stir rate of about 100 rpm to about 200 rpm. In some embodiments, Step d) is conducted at a stir rate of about 125 rpm to about 175 rpm. In some embodiments, Step d) is conducted at a stir rate of about 150 rpm. Step e) - Cooling the Suspension to Form the Crystalline Free-Plate Habit of L-Arginine Salt of (R)-2-(7-(4-Cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo- penta[b]indol-3-yl)acetic Acid. In some embodiments, cooling the suspension in Step e) is conducted at a rate of about 8.8°C / hour to about 14.4°C / hour. In some embodiments, cooling the suspension in Step e) is conducted at a rate of about 9.4°C / hour to about 13.8°C / hour. In some embodiments, cooling the suspension in Step e) is conducted at a rate of about 9.9°C / hour to about 13.2°C / hour. In some embodiments, cooling the suspension in Step e) is conducted at a rate of about 10.5°C / hour to about 12.6°C / hour. In some embodiments, cooling the suspension in Step e) is conducted at a rate of about 10°C / hour to about 12°C / hour. In some embodiments, after cooling in Step e) the temperature of the suspension is about 15°C to about 40°C. In some embodiments, after cooling in Step e) the temperature of the suspension is about 20°C to about 30°C. In some embodiments, after cooling in Step e) the temperature of the suspension is about 22°C to about 24°C. In some embodiments, Step e) is conducted at a stir rate of about 100 rpm to about 200 rpm. In some embodiments, Step e) is conducted at a stir rate of about 125 rpm to about 175 rpm. In some embodiments, Step e) is conducted at a stir rate of about 150 rpm. In some embodiments, the method further comprises the step of isolating the crystalline free- plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3-<com:Math><semantics>(trifluoromethyl)<annotation encoding="application / x-tex">(trifluoromethyl)< / annotation>< / semantics>< / com:Math>benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid. In some embodiments, the step of isolating comprises filtering the crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid from the suspension. In some embodiments, the step of isolating comprises filtering the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−<annotation encoding="application / x-tex">(R)-2-(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid from the suspension and drying the crystalline free-plate habit of L-arginine salt at a reduced pressure. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of (R)-2- (7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has an onset temperature of 205.0°C to 208.5°C as determined by differential scanning calorimetry at a scan rate of 10°C / minute. In some embodiments, after filtering, the crystalline free-plate habit of L- arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid has an onset temperature of 205.5°C to 208.5°C as determined by differential scanning calorimetry at a scan rate of 10°C / minute. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has an onset temperature of 206.5°C to 208.5°C as determined by differential scanning calorimetry at a scan rate of 10°C / minute. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has an onset temperature of 207.0°C to 208.1°C as determined by differential scanning calorimetry at a scan rate of 10°C / minute. In some embodiments, after filtering, the crystalline free-plate habit of L- arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a differential scanning calorimetry trace conducted at a scan rate of 10°C / minute comprising an endotherm substantially as depicted in any one of Figures 6 to 10. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of (R)-2- (7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a differential scanning calorimetry trace conducted at a scan rate of 10°C / minute comprising an endotherm substantially as depicted in any one of Figures 6 to 10 and Figures 22 to 25. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−<annotation encoding="application / x-tex">(R)-2-(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.3% weight or less at 90% RH. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.2% weight or less at 90% RH. The DMS features reported herein can also vary by plus or minus about <com:Math><semantics>0.15%<annotation encoding="application / x-tex">0.15\%< / annotation>< / semantics>< / com:Math> weight change (i.e., <com:Math><semantics>±0.15%<annotation encoding="application / x-tex">\pm 0.15\%< / annotation>< / semantics>< / com:Math> weight change). In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2- (7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a total impurity profile by achiral HPLC of less than or equal to 0.5% by area. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−<annotation encoding="application / x-tex">(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a total impurity profile by achiral HPLC of less than or equal to 0.3% by area. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a total impurity profile by achiral HPLC of less than or equal to 0.2% by area. In some embodiments, the method further comprises the step of formulating the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3-<com:Math><semantics>(trifluoromethyl)<annotation encoding="application / x-tex">(trifluoromethyl)< / annotation>< / semantics>< / com:Math>benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid to form a pharmaceutical composition. In some embodiments, the method further comprises the step of admixing the crystalline free- plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3-<com:Math><semantics>(trifluoromethyl)<annotation encoding="application / x-tex">(trifluoromethyl)< / annotation>< / semantics>< / com:Math>benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid with a pharmaceutical excipient to form a pharmaceutical composition. One aspect of the present invention relates to methods for preparing a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid, the method comprising the steps of: a) hydrolyzing a compound of Formula (IIa): [Image disponible dans le document PDF, Image available in the PDF document] wherein R<com:Sup>3< / com:Sup> is C<com:Sub>1< / com:Sub>-C<com:Sub>6< / com:Sub> alkyl; in the presence of a hydrolyzing mixture comprising a lipase and a hydrolyzing-step solvent to form <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3-<com:Math><semantics>(trifluoromethyl)<annotation encoding="application / x-tex">(trifluoromethyl)< / annotation>< / semantics>< / com:Math>benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid; b) adding L-arginine to a salt-forming mixture comprising <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math> to form a first mixture comprising L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; c) heating the first mixture to a first heating temperature; d) adding a first additional amount of the 2-propanol to the first mixture to form a suspension; and e) cooling the suspension to form the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>- 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. Further description of the embodiments for these methods as related to Steps a) to e) can be found herein, for example, see Steps a) to e) respectively, supra. Also described herein are methods for preparing a crystalline free-plate habit of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3- yl)acetic acid starting from (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid. Accordingly, one aspect of the present invention relates to methods for preparing a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid, the method comprising the steps of: a) adding L-arginine to a salt-forming mixture comprising <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, a water-miscible anti-solvent, and <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math> to form a first mixture comprising L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; b) heating the first mixture to a first temperature; c) adding a first additional amount of the water-miscible anti-solvent to the first mixture to form a suspension; and d) cooling the suspension to form the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>- 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. Further description of the embodiments for these methods as related to Steps a) to d) can be found herein, for example, see Steps b) to e) respectively, supra. Another aspect of the present invention relates to methods for preparing a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid, the method comprising the steps of: a) adding L-arginine to a salt-forming mixture comprising <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math> to form a first mixture comprising L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; b) heating the first mixture to a first temperature; c) adding a first additional amount of 2-propanol to the first mixture to form a suspension; and d) cooling the suspension to form the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>- 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. Further description of the embodiments for these methods as related to Steps a) to d) can be found herein, for example, see Steps b) to e) respectively, supra. One aspect of the present invention relates to methods for preparing a crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−(trifluoromethyl)benzyloxy)−1,2,3,4−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-< / annotation>< / semantics>< / com:Math> tetrahydrocyclopenta[b]indol-3-yl)acetic acid, the method comprising the steps of: a) hydrolyzing a compound of Formula (IIa): [Image disponible dans le document PDF, Image available in the PDF document] wherein <com:Math><semantics>ℝ3<annotation encoding="application / x-tex">\mathbb{R}^3< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>ℂ1<annotation encoding="application / x-tex">\mathbb{C}_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>ℂ6<annotation encoding="application / x-tex">\mathbb{C}_6< / annotation>< / semantics>< / com:Math> alkyl; in the presence of a hydrolyzing mixture comprising a lipase and a hydrolyzing-step solvent to form <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3-<com:Math><semantics>(trifluoromethyl)<annotation encoding="application / x-tex">(trifluoromethyl)< / annotation>< / semantics>< / com:Math>benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid; b) forming a first mixture comprising L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, a water-miscible anti-solvent, and H<com:Sub>2< / com:Sub>O; C) heating the first mixture to a first heating temperature to form a second mixture; d) adding a first additional amount of the water-miscible anti-solvent to the second mixture while maintaining the first heating temperature to form a suspension; e) cooling the suspension to a first cooling temperature and thereafter heating to a second heating temperature; f) cycling Step e) optionally one or more times, wherein the first cooling temperature at each cycle may be the same or different and the second heating temperature at each cycle may be the same or different; and g) cooling the suspension to a final cooling temperature to form the crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid. In some embodiments, the method for preparing a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)acetic acid is conducted under an inert atmosphere. In some embodiments, the method is conducted under an inert atmosphere comprising nitrogen or argon. In some embodiments, the method is conducted under an inert atmosphere comprising nitrogen. Step a) - Hydrolyzing a Compound of Formula (IIa). In some embodiments, the hydrolyzing in Step a) is conducted under an inert atmosphere. In some embodiments, the hydrolyzing in Step a) is conducted under an inert atmosphere comprising nitrogen or argon. In some embodiments, the hydrolyzing in Step a) is conducted under an inert atmosphere comprising nitrogen. In some embodiments, R<com:Sup>3< / com:Sup> is methyl or ethyl. In some embodiments, R<com:Sup>3< / com:Sup> is ethyl. In some embodiments, the lipase is Candida Antarctica lipase B. In some embodiments, the lipase is immobilized Candida Antarctica lipase B. In some embodiments, the hydrolyzing-step solvent comprises dimethylformamide (DMF), dimethylacetamide (DMA), dimethylsulfoxide (DMSO), tetrahydrofuran (THF), or acetonitrile. In some embodiments, the hydrolyzing-step solvent comprises acetonitrile. In some embodiments, the compound of Formula (IIa) is: [Image disponible dans le document PDF, Image available in the PDF document] the lipase is immobilized Candida Antarctica lipase B; and the hydrolyzing-step solvent comprises acetonitrile. In some embodiments, the hydrolyzing is conducted in the presence of a phosphate buffer. In some embodiments, the hydrolyzing is conducted in the presence of a phosphate buffer at a pH of about 6.0 to about 9.0. In some embodiments, the hydrolyzing is conducted in the presence of a phosphate buffer at a pH of about 6.9 to about 8.1. In some embodiments, the hydrolyzing is conducted in the presence of a phosphate buffer at a pH of about 7.0 to about 8.5. In some embodiments, the hydrolyzing is conducted in the presence of a phosphate buffer at a pH of about 7.3 to about 8.3. In some embodiments, the hydrolyzing is conducted in the presence of a phosphate buffer at a pH of about 7.6 to about 8.0. In some embodiments, the hydrolyzing is conducted in the presence of a phosphate buffer at a pH of about 7.8. In some embodiments, the phosphate buffer is a sodium phosphate buffer. In some embodiments, the phosphate buffer is a potassium phosphate buffer. In some embodiments, the hydrolyzing is conducted at a temperature of about 0°C to about 75°C. In some embodiments, the hydrolyzing is conducted at a temperature of about 20°C to about 65°C. In some embodiments, the hydrolyzing is conducted at a temperature of about 30°C to about 55°C. In some embodiments, the hydrolyzing is conducted at a temperature of about 35°C to about 45°C. In some embodiments, the hydrolyzing further comprises the step of isolating the <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−<annotation encoding="application / x-tex">(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. In some embodiments, after the isolating, the <com:Math><semantics>(R)−2−(7−(4−cyclopenty)1−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopenty)1-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has an enantiomeric excess of about 95% or greater. In some embodiments, after the isolating, the (R)-2-(7-(4-cyclopentyl- 3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has an enantiomeric excess of about 98% or greater. In some embodiments, after the isolating, the <com:Math><semantics>(R)−2−(7−(4−<annotation encoding="application / x-tex">(R)-2-(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has an enantiomeric excess of about 99% or greater. In some embodiments, after hydrolyzing in Step a), the <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid is not isolated. In some embodiments, after hydrolyzing in Step a), the <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid is present in an amount of at least 40% as determined by HPLC. In some embodiments, after the hydrolyzing, the <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>- 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid is present in an amount of at least 45% as determined by HPLC. Step b) – Forming a First Mixture. In some embodiments, forming a first mixture in Step b) is conducted under an inert atmosphere. In some embodiments, forming a first mixture in Step b) is conducted under an inert atmosphere comprising argon or nitrogen. In some embodiments, forming a first mixture in Step b) is conducted under an inert atmosphere comprising nitrogen. It is understood that forming a first mixture comprising L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−<annotation encoding="application / x-tex">(R)-2-(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, a water-miscible anti-solvent, and H<com:Sub>2< / com:Sub>O, may be performed in any manner routine to the skilled artisan. By way of example, forming the first mixture may comprise forming the L-arginine salt by reacting L-arginine with (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid; and mixing the L-arginine salt, the water-miscible anti- solvent, and <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math>. By way of example, forming the first mixture may comprise forming a mixture of (R)-2-(7-(4- cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, the water-miscible anti-solvent and <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math>; and reacting the L-arginine with (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid to form the first mixture. By way of example, forming the first mixture may comprise forming a mixture of (R)-2-(7-(4- cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and the water-miscible anti-solvent; and reacting the L-arginine as an aqueous slurry or solution with (R)-2- (7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid to form the first mixture. By way of example, forming the first mixture may comprise forming a mixture of (R)-2-(7-(4- cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, the water-miscible anti-solvent and the L-arginine; and adding H<com:Sub>2< / com:Sub>O to form the first mixture. Accordingly, in some embodiments, forming the first mixture in Step b) comprises the step of adding L-arginine and H<com:Sub>2< / com:Sub>O, either together or separately in any order, to a salt-forming mixture comprising (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid and the water-miscible anti-solvent to form the first mixture. In some embodiments, the adding L-arginine and H<com:Sub>2< / com:Sub>O is conducted under an inert atmosphere. In some embodiments, the adding L-arginine and H<com:Sub>2< / com:Sub>O is conducted under an inert atmosphere comprising argon or nitrogen. In some embodiments, the adding L-arginine and H<com:Sub>2< / com:Sub>O is conducted under an inert atmosphere comprising nitrogen. In some embodiments, the water-miscible anti-solvent comprises a solvent selected from the group consisting of: acetonitrile, acetone, tetrahydrofuran, and C<com:Sub>2< / com:Sub>-C<com:Sub>4< / com:Sub> alkanol. In some embodiments, the water-miscible anti-solvent comprises a solvent selected from the group consisting of: acetonitrile, acetone, tetrahydrofuran, ethanol, 1-propanol, 2-propanol, and 1-butanol. In some embodiments, the water-miscible anti-solvent comprises 2-propanol. In some embodiments, prior to adding the L-arginine and H<com:Sub>2< / com:Sub>O, the salt-forming mixture comprises (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro- cyclopenta[b]indol-3-yl)acetic acid and 2-propanol in a weight ratio of about 1.0:3.0 to about 1.0:11.0. In some embodiments, prior to adding the L-arginine and <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math>, the salt-forming mixture comprises <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>- 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid and 2-propanol in a weight ratio of about 1.0:4.0 to about 1.0:10.0. In some embodiments, prior to adding the L-arginine and <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math>, the salt-forming mixture comprises (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid and 2-propanol in a weight ratio of about 1.0:5.0 to about 1.0:9.0. In some embodiments, prior to adding the L-arginine and <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math>, the salt-forming mixture comprises (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)- 1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid and 2-propanol in a weight ratio of about 1.0:6.0 to about 1.0:8.0. In some embodiments, the molar ratio between <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L-arginine is about 1.0:0.8 to about 1.0:1.2. In some embodiments, the molar ratio between <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L-arginine is about 1.0:0.9 to about 1.0:1.2. In some embodiments, the molar ratio between (R)-2-(7-(4-cyclopentyl- 3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L-arginine is about 1.0:1.0 to about 1.0:1.2. In some embodiments, the molar ratio between <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-< / annotation>< / semantics>< / com:Math> 3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L-arginine is about 1.0:0.93 to about 1.0:1.01. In some embodiments, the molar ratio between <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−<annotation encoding="application / x-tex">(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L- arginine is about 1.0:0.93 to about 1.0:0.97. In some embodiments, the molar ratio between <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−<annotation encoding="application / x-tex">(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L- arginine is about 1.0:1.0. In some embodiments, the molar ratio between <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L-arginine is about 1.0:0.95. In some embodiments, the weight ratio of L-arginine and <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math> is about 1.0:0.4 to about 1.0:2.3. In some embodiments, the weight ratio of L-arginine and H<com:Sub>2< / com:Sub>O is about 1.0:1.6 to about 1.0:2.1. In some embodiments, the weight ratio of L-arginine and H<com:Sub>2< / com:Sub>O is about 1.0:0.8 to about 1.0:1.9. In some embodiments, the weight ratio of L-arginine and H<com:Sub>2< / com:Sub>O is about 1.0:1.0 to about 1.0:1.7. In some embodiments, the weight ratio of L-arginine and H<com:Sub>2< / com:Sub>O is about 1.0:1.1 to about 1.0:1.6. In some embodiments, the weight ratio of L-arginine and H<com:Sub>2< / com:Sub>O is about 1.0:1.2 to about 1.0:1.5. In some embodiments, the salt-forming mixture prior to the adding L-arginine is at a temperature of about 15°C to about 83°C. In some embodiments, the salt-forming mixture prior to the adding L-arginine is at a temperature of about 18°C to about 80°C. In some embodiments, the salt- forming mixture prior to the adding L-arginine is at a temperature of about 20°C to about 40°C. In some embodiments, the salt-forming mixture prior to the adding L-arginine is at a temperature of about 18°C to about 30°C. In some embodiments, the adding L-arginine is conducted by adding L-arginine as an aqueous slurry to the salt-forming mixture. In some embodiments, the adding L-arginine is conducted by adding L-arginine as a solid to the salt-forming mixture. In some embodiments, the adding L-arginine to the salt-forming mixture is conducted by adding L-arginine as a solid to the salt-forming mixture substantially all at once. The phrase "substantially all at once" or "all at once" refers to the addition of all of the L-arginine to the salt- forming mixture at one time with the only limitation that is placed on the addition is by any limitation associated with the equipment used. In some embodiments, the adding L-arginine to the salt-forming mixture is conducted by adding L-arginine as a solid to the salt-forming mixture over a period of about 30 minutes. In some embodiments, the adding L-arginine to the salt-forming mixture is conducted by adding L-arginine as a solid to the salt-forming mixture over a period of about 1 hour. In some embodiments, the adding L- arginine to the salt-forming mixture is conducted by adding L-arginine as a solid to the salt-forming mixture over a period of about 2 hours. In some embodiments, the salt-forming mixture comprises <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−cyclopentyl))<annotation encoding="application / x-tex">(R)-2-(7-(4-\text{cyclopentyl}-3-\text{cyclopentyl}))< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.0:3.0:0.05 to about 1.0:11.0:1.0. In some embodiments, the salt- forming mixture comprises (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro- cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.0:4.0:0.1 to about 1.0:10.0:0.9. In some embodiments, the salt-forming mixture comprises (R)-2-(7-(4-cyclopentyl- 3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.0:5.0:0.15 to about 1.0:9.0:0.8. In some embodiments, the salt- forming mixture comprises (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro- cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.0:6.0:0.25 to about 1.0:8.0:0.7. In some embodiments, the salt-forming mixture comprises <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.00:4.98:0.94 to about 1.00:7.46:1.40, about 1.00:5.29:0.99 to about 1.00:7.15:1.35, about 1.00:5.60:1.05 to about 1.00:6.84:1.29, about 1.00:5.72:1.08 to about 1.00:6.72:1.26, about 1.00:5.85:1.10 to about 1.00:6.59:1.24, about 1.00:5.97:1.12 to about 1.00:6.47:1.22, about 1.00:6.10:1.15 to about 1.00:6.34:1.19, or about 1.00:6.22:1.17. In some embodiments, the salt-forming mixture during the adding L-arginine is at a temperature of about 15°C to about 83°C. In some embodiments, the salt-forming mixture during the adding L-arginine is at a temperature of about 18°C to about 80°C. In some embodiments, the salt- forming mixture during the adding L-arginine is at a temperature of about 20°C to about 40°C. In some embodiments, the salt-forming mixture during the adding L-arginine is at a temperature of about 18°C to about 30°C. In some embodiments, the adding L-arginine is conducted by adding L-arginine as an aqueous solution to the salt-forming mixture. In some embodiments, the adding L-arginine is conducted by adding L-arginine to the salt- forming mixture wherein L-arginine is a solution of about 2.1M to about 2.3M aqueous solution at a temperature of about 50°C to about 75°C. In some embodiments, forming the first mixture in Step b) is conducted at a stir rate of about 100 rpm to about 200 rpm. In some embodiments, forming the first mixture in Step b) is conducted at a stir rate of about 125 rpm to about 175 rpm. In some embodiments, forming the first mixture in Step b) is conducted at a stir rate of about 150 rpm. Step c) - Heating the First Mixture to a First Heating Temperature to form a Second Mixture. In some embodiments, the first heating temperature is about 20°C to about 85°C. In some embodiments, the first heating temperature is about 20°C to about 83°C. In some embodiments, the first heating temperature is about 20°C to about 55°C. In some embodiments, the first heating temperature is about 25°C to about 45°C. In some embodiments, the first heating temperature is about 50°C to about 83°C. In some embodiments, the first heating temperature is about 60°C to about 80°C. In some embodiments, the first heating temperature is about 70°C to about 80°C. In some embodiments, the first heating temperature is about 79°C to about 85°C. In some embodiments, an optional amount of H<com:Sub>2< / com:Sub>O is added to the second mixture. In some embodiments, when the optional amount of <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math> is added to the second mixture, the weight amount of water added is about 0.4 to about 2.3 times the weight of L-arginine originally added in forming the first mixture. In some embodiments, when the optional amount of <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math> is added to the second mixture, the weight amount of water added is about 1.0:1.6 to about 1.0:2.1 times the weight of L-arginine originally added in forming the first mixture. In some embodiments, when water is added to the second mixture, the weight amount of water added is about 1.0:0.8 to about 1.0:1.9 times the weight of L-arginine originally added in forming the first mixture. In some embodiments, when water is added to the second mixture, the weight amount of water added is about 1.0:1.0 to about 1.0:1.7 times the weight of L- arginine originally added in forming the first mixture. In some embodiments, when water is added to the second mixture, the weight amount of water added is about 1.0:1.1 to about 1.0:1.6 times the weight of L-arginine originally added in forming the first mixture. In some embodiments, when water is added to the second mixture, the weight amount of water added is about 1.0:1.2 to about 1.0:1.5 times the weight of L-arginine originally added in forming the first mixture. In some embodiments, the second mixture is substantially a homogeneous solution. In some embodiments, Step c) is conducted at a stir rate of about 100 rpm to about 200 rpm. In some embodiments, Step c) is conducted at a stir rate of about 125 rpm to about 175 rpm. In some embodiments, Step c) is conducted at a stir rate of about 150 rpm. Step d) - Adding a First Additional Amount of the Water-Miscible Anti-Solvent to the Second Mixture while maintaining the First Heating Temperature to Form a Suspension. In some embodiments, the weight ratio of L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:5.46 to about 1.00:8.20. In some embodiments, the weight ratio of L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:4.70 to about 1.00:7.50. In some embodiments, the weight ratio of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:5.20 to about 1.00:7.00. In some embodiments, the weight ratio of L-arginine salt of (R)-2-(7-(4- cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:5.70 to about 1.00:6.50. In some embodiments, the weight ratio of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−(trifluoromethyl)benzyloxy)−1,2,3,4−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-< / annotation>< / semantics>< / com:Math> tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:5.90 to about 1.00:6.30. In some embodiments, the weight ratio of L-arginine salt of (R)-2-(7-(4- cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:5.95 to about 1.00:6.25. In some embodiments, the weight ratio of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:6.00 to about 1.00:6.20. In some embodiments, the weight ratio of L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:5.46 to about 1.00:8.20, about 1.00:5.81 to about 1.00:7.86, about 1.00:6.15 to about 1.00:7.51, about 1.00:6.28 to about 1.00:7.38, about 1.00:6.42 to about 1.00:7.24, about 1.00:6.56 to about 1.00:7.10, about 1.00:6.69 to about 1.00:6.97, or about 1.00:6.83. In some embodiments, the first additional amount of the water-miscible anti-solvent is added during a first time point and a second time point. In some embodiments, about 5% to about 15% of the first additional amount of the water- miscible anti-solvent is added at the first time point. In some embodiments, about 7% to about 13% of the first additional amount of the water- miscible anti-solvent is added at the first time point. In some embodiments, about 8% to about 12% of the first additional amount of the water- miscible anti-solvent is added at the first time point. In some embodiments, about 9% to about 11% of the first additional amount of the water-miscible anti-solvent is added at the first time point. In some embodiments, the first additional amount of the water-miscible anti-solvent is added at the first time point to form a cloudy mixture. In some embodiments, prior to the second time point, a seed crystal of L-arginine salt of (R)-2- (7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid is optionally added. In some embodiments, the first additional amount of the water-miscible anti-solvent is added at the second time point at a rate to complete the addition in about 1.00 hour or greater. In some embodiments, the first additional amount of the water-miscible anti-solvent is added at the second time point at a rate to complete the addition in about 1.00 hour to about 6.00 hours. In some embodiments, the first additional amount of the water-miscible anti-solvent is added at the second time point at a rate to complete the addition in about 1.00 hour to about 5.00 hours. In some embodiments, the first additional amount of the water-miscible anti-solvent is added at the second time point at a rate to complete the addition in about 1.00 hour to about 4.00 hours. In some embodiments, the first additional amount of the water-miscible anti-solvent is added at the second time point at a rate to complete the addition in about 1.00 hour to about 3.00 hours. In some embodiments, the first additional amount of the water-miscible anti-solvent is added at the second time point at a rate to complete the addition in about 1.00 hour to about 2.00 hours. In some embodiments, the first heating temperature is maintained during the addition of the first additional amount of 2-propanol to the second mixture. In some embodiments, Step d) is conducted at a stir rate of about 100 rpm to about 200 rpm. In some embodiments, Step d) is conducted at a stir rate of about 125 rpm to about 175 rpm. In some embodiments, Step d) is conducted at a stir rate of about 150 rpm. Step e) - Cooling the Suspension to a First Cooling Temperature and Thereafter Heating to a Second Heating Temperature. In some embodiments, cooling the suspension to the first cooling temperature in Step e) is conducted at a rate of about 8.80°C / hour to about 14.40°C / hour. In some embodiments, cooling the suspension to the first cooling temperature in Step e) is conducted at a rate of about 9.35°C / hour to about 13.80°C / hour. In some embodiments, cooling the suspension to the first cooling temperature in Step e) is conducted at a rate of about 9.90°C / hour to about 13.20°C / hour. In some embodiments, cooling the suspension to the first cooling temperature in Step e) is conducted at a rate of about 10.45°C / hour to about 12.60°C / hour. In some embodiments, cooling the suspension to the first cooling temperature in Step e) is conducted at a rate of about 10°C / hour to about 12°C / hour. In some embodiments, cooling the suspension to the first cooling temperature in Step e) is conducted at a rate of about 9°C / hour to about 11°C / hour. In some embodiments, cooling the suspension to the first cooling temperature in Step e) is conducted at a rate of about 9.5°C / hour to about 10.5°C / hour. In some embodiments, the first cooling temperature in Step e) is about 15°C to about 40°C. In some embodiments, the first cooling temperature in Step e) is about 20°C to about 30°C. In some embodiments, the first cooling temperature in Step e) is about 22°C to about 24°C. In some embodiments, the first cooling temperature in Step e) is about 18°C to about 22°C. In some embodiments, the first cooling temperature is maintained for at least 1 hour prior to heating to the second heating temperature. In some embodiments, the second heating temperature in Step e) is about 65°C to about 83°C. In some embodiments, the second heating temperature in Step e) is about 70°C to about 80°C. In some embodiments, the second heating temperature in Step e) is about 70°C to about 75°C. In some embodiments, the second heating temperature in Step e) is about 69°C to about 73°C. In some embodiments, after heating to the second heating temperature, the second heating temperature is maintained for at least 30 minutes. In some embodiments, Step e) is conducted at a stir rate of about 100 rpm to about 200 rpm. In some embodiments, Step e) is conducted at a stir rate of about 125 rpm to about 175 rpm. In some embodiments, Step e) is conducted at a stir rate of about 150 rpm. Step f) – Cycling Step e) Optionally One or More Times. It is understood that when cycling Step e) more than once that the first cooling temperature at each cycle may be the same or different and said second heating temperature at each cycle may be the same or different. Two Cycles In some embodiments, the cycling in Step f) comprises the cycling Step e) two times. In some embodiments, cycling Step e) two times comprises cooling the suspension to a first cycling cooling temperature, heating the suspension to a first cycling heating temperature, cooling the suspension to a second cycling cooling temperature, and heating the suspension to a second cycling heating temperature. In some embodiments, the first cycling cooling temperature is about 16°C to about 26°C, the first heating cycling temperature is about 55°C to about 65°C, the second cycling cooling temperature is about 26°C to about 36°C, and the second cycling heating temperature is about 45°C to about 55°C. In some embodiments, the first cycling cooling temperature is about 19°C to about 23°C, the first heating cycling temperature is about 58°C to about 62°C, the second cycling cooling temperature is about 29°C to about 33°C, and the second cycling heating temperature is about 48°C to about 52°C. In some embodiments, cooling to each cooling temperature is conducted at a substantially different cooling rate. In some embodiments, cooling to each cooling temperature is conducted at a different cooling rate. In some embodiments, the cycling in Step f) comprises the cycling Step e) two times. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 10.0°C / hour to about 15.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 11.0°C / hour to about 14.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 12.0°C / hour to about 13.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 12.5°C / hour. In some embodiments, the cycling in Step f) comprises the cycling Step e) two times. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 7.5°C / hour to about 12.5°C / hour. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 8.5°C / hour to about 11.5°C / hour. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 9.5°C / hour to about 10.5°C / hour. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 10.0°C / hour. Three Cycles In some embodiments, the cycling in Step f) comprises the cycling Step e) three times. In some embodiments, cycling Step e) three times comprises: cooling the suspension to a first cycling cooling temperature, heating the suspension to a first cycling heating temperature, cooling the suspension to a second cycling cooling temperature, heating the suspension to a second cycling heating temperature, cooling the suspension to a third cycling cooling temperature, and heating the suspension to a third cycling heating temperature. In some embodiments, the first cycling cooling temperature is about 16°C to about 26°C, the first heating cycling temperature is about 66°C to about 76°C, the second cycling cooling temperature is about 16°C to about 26°C, the second cycling heating temperature is about 55°C to about 65°C, the third cycling cooling temperature is about 26°C to about 36°C, and the third cycling heating temperature is about 45°C to about 55°C. In some embodiments, the first cycling cooling temperature is about 19°C to about 23°C, the first heating cycling temperature is about 69°C to about 73°C, the second cycling cooling temperature is about 19°C to about 23°C, the second cycling heating temperature is about 58°C to about 62°C, the third cycling cooling temperature is about 29°C to about 33°C, and the third cycling heating temperature is about 48°C to about 52°C. In some embodiments, cooling to each cooling temperature is conducted at a substantially different cooling rate. In some embodiments, cooling to each cooling temperature is conducted at a different cooling rate. In some embodiments, cooling to the first cycling cooling temperature and the second cycling cooling temperature are each conducted at substantially the same cooling rate. In some embodiments, the cycling in Step f) comprises the cycling Step e) three times. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 10.0°C / hour to about 15.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 11.0°C / hour to about 14.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 12.0°C / hour to about 13.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 12.5°C / hour. In some embodiments, the cycling in Step f) comprises the cycling Step e) three times. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 10.0°C / hour to about 15.0°C / hour. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 11.0°C / hour to about 14.0°C / hour. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 12.0°C / hour to about 13.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 12.5°C / hour. In some embodiments, the cycling in Step f) comprises the cycling Step e) three times. In some embodiments, cooling to the third cycling cooling temperature is conducted at a rate of about 7.5°C / hour to about 12.5°C / hour. In some embodiments, cooling to the third cycling cooling temperature is conducted at a rate of about 8.5°C / hour to about 11.5°C / hour. In some embodiments, cooling to the third cycling cooling temperature is conducted at a rate of about 9.5°C / hour to about 10.5°C / hour. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 10.0°C / hour. Four Cycles In some embodiments, the cycling in Step f) comprises the cycling Step e) four times. In some embodiments, cycling Step e) four times comprises: cooling the suspension to a first cycling cooling temperature, heating the suspension to a first cycling heating temperature, cooling the suspension to a second cycling cooling temperature, heating the suspension to a second cycling heating temperature, cooling the suspension to a third cycling cooling temperature, heating the suspension to a third cycling heating temperature, cooling the suspension to a fourth cycling cooling temperature, and heating the suspension to a fourth cycling heating temperature. In some embodiments, the first cycling cooling temperature is about 16°C to about 26°C, the first heating cycling temperature is about 66°C to about 76°C, the second cycling cooling temperature is about 16°C to about 26°C, the second cycling heating temperature is about 66°C to about 76°C, the third cycling cooling temperature is about 16°C to about 26°C, the third cycling heating temperature is about 55°C to about 65°C, the fourth cycling cooling temperature is about 26°C to about 36°C, and the fourth cycling heating temperature is about 45°C to about 55°C. In some embodiments, the first cycling cooling temperature is about 19°C to about 23°C, the first heating cycling temperature is about 69°C to about 73°C, the second cycling cooling temperature is about 19°C to about 23°C, the second cycling heating temperature is about 69°C to about 73°C, the third cycling cooling temperature is about 19°C to about 23°C, the third cycling heating temperature is about 58°C to about 62°C, the fourth cycling cooling temperature is about 29°C to about 33°C, and the fourth cycling heating temperature is about 48°C to about 52°C. In some embodiments, cooling to each cooling temperature is conducted at a substantially different cooling rate. In some embodiments, cooling to each cooling temperature is conducted at a different cooling rate. In some embodiments, cooling to the first cycling cooling temperature, the second cycling cooling temperature, and the third cycling cooling temperature are each conducted at substantially the same cooling rate. In some embodiments, the cycling in Step f) comprises the cycling Step e) four times. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 10.0°C / hour to about 15.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 11.0°C / hour to about 14.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 12.0°C / hour to about 13.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 12.5°C / hour. In some embodiments, the cycling in Step f) comprises the cycling Step e) four times. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 10.0°C / hour to about 15.0°C / hour. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 11.0°C / hour to about 14.0°C / hour. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 12.0°C / hour to about 13.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 12.5°C / hour. In some embodiments, the cycling in Step f) comprises the cycling Step e) four times. In some embodiments, cooling to the third cycling cooling temperature is conducted at a rate of about 10.0°C / hour to about 15.0°C / hour. In some embodiments, cooling to the third cycling cooling temperature is conducted at a rate of about 11.0°C / hour to about 14.0°C / hour. In some embodiments, cooling to the third cycling cooling temperature is conducted at a rate of about 12.0°C / hour to about 13.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 12.5°C / hour. In some embodiments, the cycling in Step f) comprises the cycling Step e) four times. In some embodiments, cooling to the fourth cycling cooling temperature is conducted at a rate of about 7.5°C / hour to about 12.5°C / hour. In some embodiments, cooling to the fourth cycling cooling temperature is conducted at a rate of about 8.5°C / hour to about 11.5°C / hour. In some embodiments, cooling to the fourth cycling cooling temperature is conducted at a rate of about 9.5°C / hour to about 10.5°C / hour. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 10.0°C / hour. In some embodiments, Step f) is conducted at a stir rate of about 100 rpm to about 200 rpm. In some embodiments, Step f) is conducted at a stir rate of about 125 rpm to about 175 rpm. In some embodiments, Step f) is conducted at a stir rate of about 150 rpm. Step g) - Cooling the Suspension to a Final Cooling Temperature to Form the Crystalline Free-Plate Habit of L-Arginine Salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-Cyclopentyl-3-<com:Math><semantics>(trifluoromethyl)<annotation encoding="application / x-tex">(trifluoromethyl)< / annotation>< / semantics>< / com:Math>benzyloxy)- 1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic Acid. In some embodiments, cooling the suspension in Step g) is conducted at a rate of about 7.5°C / hour to about 12.5°C / hour. In some embodiments, cooling the suspension in Step g) is conducted at a rate of about 8.5°C / hour to about 11.5°C / hour. In some embodiments, cooling the suspension in Step g) is conducted at a rate of about 9.5°C / hour to about 10.5°C / hour. In some embodiments, cooling the suspension in Step g) is conducted at a rate of about 10.0°C / hour. In some embodiments, cooling the suspension in Step g) is conducted at a rate of about 8.8°C / hour to about 14.4°C / hour. In some embodiments, cooling the suspension in Step g) is conducted at a rate of about 9.4°C / hour to about 13.8°C / hour. In some embodiments, cooling the suspension in Step g) is conducted at a rate of about 9.9°C / hour to about 13.2°C / hour. In some embodiments, cooling the suspension in Step g) is conducted at a rate of about 10.5°C / hour to about 12.6°C / hour. In some embodiments, cooling the suspension in Step g) is conducted at a rate of about 10°C / hour to about 12°C / hour. In some embodiments, after cooling in Step g) the temperature of the suspension is about 15°C to about 40°C. In some embodiments, after cooling in Step g) the temperature of the suspension is about 20°C to about 30°C. In some embodiments, after cooling in Step g) the temperature of the suspension is about 22°C to about 24°C. In some embodiments, after cooling in Step g) the temperature of said suspension is about 18°C to about 22°C. In some embodiments, Step g) is conducted at a stir rate of about 100 rpm to about 200 rpm. In some embodiments, Step g) is conducted at a stir rate of about 125 rpm to about 175 rpm. In some embodiments, Step g) is conducted at a stir rate of about 150 rpm. In some embodiments, the method further comprises the step of isolating the crystalline free- plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid. In some embodiments, the step of isolating comprises filtering the crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid from the suspension. In some embodiments, the step of isolating comprises filtering the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−<annotation encoding="application / x-tex">(R)-2-(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid from the suspension and drying the crystalline free-plate habit of L-arginine salt at a reduced pressure. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2- (7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has any one or more of the characteristics as described herein. For example, In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has an onset temperature of 205.0°C to 208.5°C as determined by differential scanning calorimetry at a scan rate of 10°C / minute. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has an onset temperature of 205.5°C to 208.5°C as determined by differential scanning calorimetry at a scan rate of 10°C / minute. In some embodiments, after filtering, the crystalline free-plate habit of L- arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−(trifluoromethyl)benzyloxy)−1,2,3,4−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-< / annotation>< / semantics>< / com:Math> tetrahydrocyclopenta[b]indol-3-yl)acetic acid has an onset temperature of 206.5°C to 208.5°C as determined by differential scanning calorimetry at a scan rate of 10°C / minute. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has an onset temperature of 207.0°C to 208.1°C as determined by differential scanning calorimetry at a scan rate of 10°C / minute. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a differential scanning calorimetry trace conducted at a scan rate of 10°C / minute comprising an endotherm substantially as depicted in any one of Figures 6 to 10. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a differential scanning calorimetry trace conducted at a scan rate of 10°C / minute comprising an endotherm substantially as depicted in any one of Figures 6 to 10 and Figures 22 to 25. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.3% weight or less at 90% RH. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.2% weight or less at 90% RH. The DMS features reported herein can also vary by plus or minus about <com:Math><semantics>0.15%<annotation encoding="application / x-tex">0.15\%< / annotation>< / semantics>< / com:Math> weight change (i.e., <com:Math><semantics>±0.15%<annotation encoding="application / x-tex">\pm 0.15\%< / annotation>< / semantics>< / com:Math> weight change). In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of (R)-2- (7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a total impurity profile by achiral HPLC of less than or equal to 0.5% by area. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−<annotation encoding="application / x-tex">(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a total impurity profile by achiral HPLC of less than or equal to 0.3% by area. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a total impurity profile by achiral HPLC of less than or equal to 0.2% by area. In some embodiments, the method further comprises the step of formulating the crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid to form a pharmaceutical composition. In some embodiments, the method further comprises the step of admixing the crystalline free- plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3-<com:Math><semantics>(trifluoromethyl)<annotation encoding="application / x-tex">(trifluoromethyl)< / annotation>< / semantics>< / com:Math>benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid with a pharmaceutical excipient to form a pharmaceutical composition. In some embodiments, the method further comprises the step of admixing the crystalline free- plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid with a pharmaceutical excipient to form a pharmaceutical composition suitable for oral, rectal, nasal, topical, buccal, sub-lingual, or vaginal, or in a form suitable for administration by inhalation, insufflation, or by a transdermal patch. In some embodiments, the pharmaceutical composition is suitable for oral administration. Also described herein are methods for preparing a crystalline free-plate habit of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3- yl)acetic acid starting from a different morphology, such as, but not limited to, spherulites / radial clusters, fine particles, agglomerates, flakes, or a mixture thereof. Accordingly, one aspect of the present invention relates to methods for preparing a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid, the method comprising the steps of: a) heating a first mixture comprising L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, a water-miscible anti-solvent, and water to a first heating temperature to form a second mixture; b) cooling the second mixture to a first cooling temperature followed by adding a first additional amount of the water-miscible anti-solvent to the second mixture while maintaining the first cooling temperature and thereafter heating to a second heating temperature to form a suspension; c) cycling Step b) optionally once or twice; and d) cooling the suspension to a second cooling temperature to form the crystalline free- plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3-<com:Math><semantics>(trifluoromethyl)<annotation encoding="application / x-tex">(trifluoromethyl)< / annotation>< / semantics>< / com:Math>benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid. In some embodiments, the water-miscible anti-solvent comprises a solvent selected from the group consisting of: acetonitrile, acetone, tetrahydrofuran, and <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math> alkanol. In some embodiments, the water-miscible anti-solvent comprises a solvent selected from the group consisting of: acetonitrile, acetone, tetrahydrofuran, ethanol, 1-propanol, 2-propanol, and 1-butanol. In some embodiments, the water-miscible anti-solvent comprises 2-propanol. In some embodiments, the L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3-<com:Math><semantics>(trifluoromethyl)<annotation encoding="application / x-tex">(trifluoromethyl)< / annotation>< / semantics>< / com:Math>- benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid in Step a) is a spherulite, a radial cluster, a fine particle, an agglomerate, a flake, or a mixture thereof. In some embodiments, the L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−(trifluoromethyl)−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)-< / annotation>< / semantics>< / com:Math> benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid in Step a) is a crystalline spherulite habit or a mixture comprising a crystalline spherulite habit. In some embodiments, the method for preparing a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)acetic acid is conducted under an inert atmosphere. In some embodiments, the method is conducted under an inert atmosphere comprising nitrogen or argon. In some embodiments, the method is conducted under an inert atmosphere comprising nitrogen. Step a) - Heating a First Mixture. In some embodiments, the first mixture comprises L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.00:3.35:0.75 to about 1.00:5.03:1.13. In some embodiments, the first mixture comprises L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−(trifluoromethyl)benzyloxy)−1,2,3,4−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-< / annotation>< / semantics>< / com:Math> tetrahydrocyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.00:3.56:0.80 to about 1.00:4.82:1.08. In some embodiments, the first mixture comprises L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.00:3.77:0.85 to about 1.00:4.61:1.03. In some embodiments, the first mixture comprises L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.00:3.85:0.86 to about 1.00:4.52:1.02. In some embodiments, the first mixture comprises L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−(trifluoromethyl)benzyloxy)−1,2,3,4−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-< / annotation>< / semantics>< / com:Math> tetrahydrocyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.00:3.94:0.88 to about 1.00:4.44:1.00. In some embodiments, the first mixture comprises L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.00:4.02:0.90 to about 1.00:4.36:0.98. In some embodiments, the first mixture comprises L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.00:4.11:0.92 to about 1.00:4.27:0.96. In some embodiments, the first mixture comprises L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3-<com:Math><semantics>(trifluoromethyl)<annotation encoding="application / x-tex">(trifluoromethyl)< / annotation>< / semantics>< / com:Math>benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.00:4.19:0.94. In some embodiments, the first mixture is at a temperature of about 10°C to about 30°C prior to heating to the first heating temperature. In some embodiments, the first mixture is at a temperature of about 15°C to about 25°C prior to heating to the first heating temperature. In some embodiments, the first heating temperature is about 60°C to about 83°C. In some embodiments, the first heating temperature is about 70°C to about 83°C. In some embodiments, the first heating temperature is about 75°C to about 80°C. In some embodiments, after heating to the first heating temperature the second mixture is substantially a homogeneous solution. In some embodiments, Step a) is conducted at a stir rate of about 50 rpm to about 250 rpm. In some embodiments, Step a) is conducted at a stir rate of about 75 rpm to about 150 rpm. Step b) - Cooling the Second Mixture to a First Cooling Temperature. In some embodiments, the first cooling temperature is about 50°C to about 70°C. In some embodiments, the first cooling temperature is about 60°C to about 70°C. In some embodiments, the first cooling temperature is about 63°C to about 67°C. In some embodiments, the first cooling temperature is maintained for at least 30 minutes. In some embodiments, adding the first additional amount of 2-propanol to the second mixture is conducted at a rate of about 107.20 g / minute to about 160.80 g / minute. In some embodiments, adding the first additional amount of 2-propanol to the second mixture is conducted at a rate of about 113.90 g / minute to about 154.10 g / minute. In some embodiments, adding the first additional amount of 2- propanol to the second mixture is conducted at a rate of about 120.60 g / minute to about 147.40 g / minute. In some embodiments, adding the first additional amount of 2-propanol to the second mixture is conducted at a rate of about 127.30 g / minute to about 140.70 g / minute. In some embodiments, adding the first additional amount of 2-propanol to the second mixture is conducted at a rate of about 134 g / minute. In some embodiments, the weight ratio of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:0.98 to about 1.00:1.47. In some embodiments, the weight ratio of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:1.04 to about 1.00:1.41. In some embodiments, the weight ratio of L-arginine salt of (R)-2-(7-(4- cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:1.10 to about 1.00:1.35. In some embodiments, the weight ratio of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:1.13 to about 1.00:1.32. In some embodiments, the weight ratio of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−<annotation encoding="application / x-tex">(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:1.15 to about 1.00:1.30. In some embodiments, the weight ratio of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3-<com:Math><semantics>(trifluoromethyl)<annotation encoding="application / x-tex">(trifluoromethyl)< / annotation>< / semantics>< / com:Math>benzyloxy)-1,2,3,4- tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:1.18 to about 1.00:1.27. In some embodiments, the weight ratio of L-arginine salt of (R)-2-(7-(4- cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:1.20 to about 1.00:1.25. In some embodiments, the weight ratio of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:1.23. In some embodiments, after adding the first additional amount of 2-propanol, the first cooling temperature is maintained for at least 1 hour prior to heating to the second heating temperature. In some embodiments, the second heating temperature is about 65°C to about 83°C. In some embodiments, the second heating temperature is about 70°C to about 80°C. In some embodiments, the second heating temperature is about 70°C to about 75°C. In some embodiments, the second heating temperature is at a temperature to retain the suspension. In some embodiments, after heating to the second heating temperature, the second heating temperature is maintained for at least 30 minutes while retaining the suspension. In some embodiments, Step b) is conducted at a stir rate of about 50 rpm to about 150 rpm. In some embodiments, Step b) is conducted at a stir rate of about 70 rpm to about 110 rpm. Step c) - Cycling Step b). In some embodiments, cycling Step b) is conducted once. In some embodiments, cycling Step b) is conducted once, wherein the cycling conditions are substantially the same conditions as used for Step b). In some embodiments, cycling Step b) is conducted once, wherein the cycling conditions are different from the conditions used for Step b); it is understood that the selected cycling conditions are still within the embodiments as described herein for Step b). In some embodiments, cycling Step b) is conducted twice. In some embodiments, cycling Step b) is conducted twice, wherein the cycling conditions for the first cycle and the second cycle are substantially the same conditions as used for Step b). In some embodiments, cycling Step b) is conducted twice, wherein at least one of the conditions for the first cycle, the second cycle, or Step b) is different; it is understood that whether or not the first cycle and / or the second cycle is different from each other or one or both of the cycles are different from Step b) that each of selected conditions for the first cycle and the second cycle are still within the embodiments as described herein for Step b). Step d) - Cooling the Suspension to a Second Cooling Temperature to Form the Crystalline Free-Plate Habit of L-Arginine Salt of (R)-2-(7-(4-Cyclopentyl-3-(trifluoro- methyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic Acid. In some embodiments, the second cooling temperature is about 50°C to about 70°C. In some embodiments, the second cooling temperature is about 60°C to about 70°C. In some embodiments, the second cooling temperature is about 63°C to about 67°C. In some embodiments, the second cooling temperature is maintained for at least 30 minutes. In some embodiments, Step d) is conducted at a stir rate of about 25 rpm to about 105 rpm. In some embodiments, Step d) is conducted at a stir rate of about 45 rpm to about 85 rpm. In some embodiments, after cooling to the second cooling temperature, the method further comprises the step of cooling the suspension to a third cooling temperature. In some embodiments, after cooling to the second cooling temperature, the method further comprises the step of cooling the suspension to a third cooling temperature of about 10°C to about 30°C. In some embodiments, after cooling to the second cooling temperature, the method further comprises the step of cooling the suspension to a third cooling temperature of about 15°C to about 25°C. In some embodiments, the cooling rate from the second cooling temperature to the third cooling temperature is about 5°C per hour to about 15°C per hour. In some embodiments, the cooling rate from the second cooling temperature to the third cooling temperature is about 8°C per hour to about 12°C per hour. In some embodiments, the cooling rate from the second cooling temperature to the third cooling temperature is about 10°C per hour. In some embodiments, the method further comprises the step of isolating the crystalline free- plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7<annotation encoding="application / x-tex">(7< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>(4<annotation encoding="application / x-tex">(4< / annotation>< / semantics>< / com:Math>-cyclopentyl-3-<com:Math><semantics>(trifluoromethyl)<annotation encoding="application / x-tex">(trifluoromethyl)< / annotation>< / semantics>< / com:Math>benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid. In some embodiments, the step of isolating comprises filtering the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−(trifluoromethyl)benzyloxy)−1,2,3,4−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-< / annotation>< / semantics>< / com:Math> tetrahydrocyclopenta[b]indol-3-yl)acetic acid from the suspension. In some embodiments, the step of isolating comprises filtering the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−<annotation encoding="application / x-tex">(R)-2-(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid from the suspension and drying the crystalline free-plate habit of L-arginine salt at a reduced pressure. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of (R)-2- (7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has an onset temperature of 205.0°C to 208.5°C as determined by differential scanning calorimetry at a scan rate of 10°C / minute. In some embodiments, after filtering, the crystalline free-plate habit of L- arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid has an onset temperature of 205.5°C to 208.5°C as determined by differential scanning calorimetry at a scan rate of 10°C / minute. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has an onset temperature of 206.5°C to 208.5°C as determined by differential scanning calorimetry at a scan rate of 10°C / minute. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has an onset temperature of 207.0°C to 208.1°C as determined by differential scanning calorimetry at a scan rate of 10°C / minute. In some embodiments, after filtering, the crystalline free-plate habit of L- arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a differential scanning calorimetry trace conducted at a scan rate of 10°C / minute comprising an endotherm substantially as depicted in any one of Figures 6 to 10. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of (R)-2- (7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a differential scanning calorimetry trace conducted at a scan rate of 10°C / minute comprising an endotherm substantially as depicted in any one of Figures 6 to 10 and Figures 22 to 25. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−<annotation encoding="application / x-tex">(R)-2-(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.3% weight or less at 90% RH. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.2% weight or less at 90% RH. The DMS features reported herein can also vary by plus or minus about <com:Math><semantics>0.15%<annotation encoding="application / x-tex">0.15\%< / annotation>< / semantics>< / com:Math> weight change (i.e., <com:Math><semantics>±0.15%<annotation encoding="application / x-tex">\pm 0.15\%< / annotation>< / semantics>< / com:Math> weight change). In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2- (7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a total impurity profile by achiral HPLC of less than or equal to 0.5% by area. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−<annotation encoding="application / x-tex">(R)-2-(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a total impurity profile by achiral HPLC of less than or equal to 0.3% by area. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has a total impurity profile by achiral HPLC of less than or equal to 0.2% by area. In some embodiments, the method further comprises the step of formulating the crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid to form a pharmaceutical composition. In some embodiments, the method further comprises the step of admixing the crystalline free- plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−(trifluoromethyl)benzyloxy)−1,2,3,4−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-< / annotation>< / semantics>< / com:Math> tetrahydrocyclopenta[b]indol-3-yl)acetic acid with a pharmaceutical excipient to form a pharmaceutical composition. One aspect of the present invention relates to methods for preparing a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid, the method comprising the steps of: a) forming a first mixture comprising L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, a water-miscible anti-solvent, and H<com:Sub>2< / com:Sub>O; b) heating the first mixture to a first heating temperature to form a second mixture; c) adding a first additional amount of the water-miscible anti-solvent to the second mixture while maintaining the first heating temperature to form a suspension; d) cooling the suspension to a first cooling temperature and thereafter heating to a second heating temperature; e) cycling Step d) optionally one or more times, wherein the first cooling temperature at each cycle may be the same or different and the second heating temperature at each cycle may be the same or different; and f) cooling the suspension to a final cooling temperature to form the crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid. Step a) – Forming a First Mixture. In some embodiments, forming a first mixture in Step a) is conducted under an inert atmosphere. In some embodiments, forming a first mixture in Step a) is conducted under an inert atmosphere comprising argon or nitrogen. In some embodiments, forming a first mixture in Step a) is conducted under an inert atmosphere comprising nitrogen. It is understood that forming a first mixture comprising L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−<annotation encoding="application / x-tex">(R)-2-(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, a water-miscible anti-solvent, and <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math>, may be performed in any manner routine to the skilled artisan, such as, the examples described supra. In some embodiments, forming the first mixture in Step a) comprises the step of adding L- arginine and <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math>, either together or separately in any order, to a salt-forming mixture comprising (R)- 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and the water-miscible anti-solvent to form the first mixture. In some embodiments, the adding L-arginine and H<com:Sub>2< / com:Sub>O is conducted under an inert atmosphere. In some embodiments, the adding L-arginine and H<com:Sub>2< / com:Sub>O is conducted under an inert atmosphere comprising argon or nitrogen. In some embodiments, the adding L-arginine and H<com:Sub>2< / com:Sub>O is conducted under an inert atmosphere comprising nitrogen. In some embodiments, the water-miscible anti-solvent comprises a solvent selected from the group consisting of: acetonitrile, acetone, tetrahydrofuran, and C<com:Sub>2< / com:Sub>-C<com:Sub>4< / com:Sub> alkanol. In some embodiments, the water-miscible anti-solvent comprises a solvent selected from the group consisting of: acetonitrile, acetone, tetrahydrofuran, ethanol, 1-propanol, 2-propanol, and 1-butanol. In some embodiments, the water-miscible anti-solvent comprises 2-propanol. In some embodiments, prior to adding the L-arginine and <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math>, the salt-forming mixture comprises (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro- cyclopenta[b]indol-3-yl)acetic acid and 2-propanol in a weight ratio of about 1.0:3.0 to about 1.0:11.0. In some embodiments, prior to adding the L-arginine and <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math>, the salt-forming mixture comprises (R)- 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid and 2-propanol in a weight ratio of about 1.0:4.0 to about 1.0:10.0. In some embodiments, prior to adding the L-arginine and <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math>, the salt-forming mixture comprises (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid and 2-propanol in a weight ratio of about 1.0:5.0 to about 1.0:9.0. In some embodiments, prior to adding the L-arginine and <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math>, the salt-forming mixture comprises (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)- 1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid and 2-propanol in a weight ratio of about 1.0:6.0 to about 1.0:8.0. In some embodiments, the molar ratio between <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-\text{cyclopentyl}-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L-arginine is about 1.0:0.8 to about 1.0:1.2. In some embodiments, the molar ratio between <com:Math><semantics>(R)−2−(7−(4−cyclopentyl-3−<annotation encoding="application / x-tex">(R)-2-(7-(4-\text{cyclopentyl-}3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L-arginine is about 1.0:0.9 to about 1.0:1.2. In some embodiments, the molar ratio between <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-< / annotation>< / semantics>< / com:Math> 3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L-arginine is about 1.0:1.0 to about 1.0:1.2. In some embodiments, the molar ratio between (R)-2-(7-(4-cyclopentyl- 3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L-arginine is about 1.0:0.93 to about 1.0:1.01. In some embodiments, the molar ratio between <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−<annotation encoding="application / x-tex">(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L- arginine is about 1.0:0.93 to about 1.0:0.97. In some embodiments, the molar ratio between <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−<annotation encoding="application / x-tex">(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L- arginine is about 1.0:1.0. In some embodiments, the molar ratio between <com:Math><semantics>(R)−2−(7−(4−cyclopentyl-3−cyclopentyl-3−cyclopentyl-3−cyclopentyl-3−cyclopentyl-3−cyclopentyl-3−cyclopentyl-3−cyclopentyl-3−<annotation encoding="application / x-tex">(R)-2-(7-(4-\text{cyclopentyl-}3-\text{cyclopentyl-}3-\text{cyclopentyl-}3-\text{cyclopentyl-}3-\text{cyclopentyl-}3-\text{cyclopentyl-}3-\text{cyclopentyl-}3-\text{cyclopentyl-}3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L-arginine is about 1.0:0.95. In some embodiments, the weight ratio of L-arginine and <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math> is about 1.0:0.4 to about 1.0:2.3. In some embodiments, the weight ratio of L-arginine and H<com:Sub>2< / com:Sub>O is about 1.0:1.6 to about 1.0:2.1. In some embodiments, the weight ratio of L-arginine and <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math> is about 1.0:0.8 to about 1.0:1.9. In some embodiments, the weight ratio of L-arginine and H<com:Sub>2< / com:Sub>O is about 1.0:1.0 to about 1.0:1.7. In some embodiments, the weight ratio of L-arginine and H<com:Sub>2< / com:Sub>O is about 1.0:1.1 to about 1.0:1.6. In some embodiments, the weight ratio of L-arginine and H<com:Sub>2< / com:Sub>O is about 1.0:1.2 to about 1.0:1.5. In some embodiments, the salt-forming mixture prior to the adding L-arginine is at a temperature of about 15°C to about 83°C. In some embodiments, the salt-forming mixture prior to the adding L-arginine is at a temperature of about 18°C to about 80°C. In some embodiments, the salt- forming mixture prior to the adding L-arginine is at a temperature of about 20°C to about 40°C. In some embodiments, the salt-forming mixture prior to the adding L-arginine is at a temperature of about 18°C to about 30°C. In some embodiments, the adding L-arginine is conducted by adding L-arginine as an aqueous slurry to the salt-forming mixture. In some embodiments, the adding L-arginine is conducted by adding L-arginine as a solid to the salt-forming mixture. In some embodiments, the adding L-arginine to the salt-forming mixture is conducted by adding L-arginine as a solid to the salt-forming mixture substantially all at once. The phrase "substantially all at once" or "all at once" refers to the addition of all of the L-arginine to the salt- forming mixture at one time with the only limitation that is placed on the addition is by any limitation associated with the equipment used. In some embodiments, the adding L-arginine to the salt-forming mixture is conducted by adding L-arginine as a solid to the salt-forming mixture over a period of about 30 minutes. In some embodiments, the adding L-arginine to the salt-forming mixture is conducted by adding L-arginine as a solid to the salt-forming mixture over a period of about 1 hour. In some embodiments, the adding L- arginine to the salt-forming mixture is conducted by adding L-arginine as a solid to the salt-forming mixture over a period of about 2 hours. In some embodiments, the salt-forming mixture comprises <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.0:3.0:0.05 to about 1.0:11.0:1.0. In some embodiments, the salt- forming mixture comprises (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro- cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.0:4.0:0.1 to about 1.0:10.0:0.9. In some embodiments, the salt-forming mixture comprises (R)-2-(7-(4-cyclopentyl- 3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.0:5.0:0.15 to about 1.0:9.0:0.8. In some embodiments, the salt- forming mixture comprises (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro- cyclopenta[b]indol-3-yl)acetic acid, 2-propanol, and water in a weight ratio of about 1.0:6.0:0.25 to about 1.0:8.0:0.7. In some embodiments, the salt-forming mixture during the adding L-arginine is at a temperature of about 15°C to about 83°C. In some embodiments, the salt-forming mixture during the adding L-arginine is at a temperature of about 18°C to about 80°C. In some embodiments, the salt- forming mixture during the adding L-arginine is at a temperature of about 20°C to about 40°C. In some embodiments, the salt-forming mixture during the adding L-arginine is at a temperature of about 18°C to about 30°C. In some embodiments, the salt-forming mixture during the adding L-arginine is at a temperature of about 15°C to about 83°C. In some embodiments, the salt-forming mixture during the adding L-arginine is at a temperature of about 18°C to about 80°C. In some embodiments, the salt- forming mixture during the adding L-arginine is at a temperature of about 20°C to about 40°C. In some embodiments, the salt-forming mixture during the adding L-arginine is at a temperature of about 18°C to about 30°C. In some embodiments, the adding L-arginine is conducted by adding L-arginine as an aqueous solution to the salt-forming mixture. In some embodiments, the adding L-arginine is conducted by adding L-arginine to the salt- forming mixture wherein L-arginine is a solution of about 2.1M to about 2.3M aqueous solution at a temperature of about 50°C to about 75°C. In some embodiments, forming the first mixture in Step a) is conducted at a stir rate of about 100 rpm to about 200 rpm. In some embodiments, forming the first mixture in Step a) is conducted at a stir rate of about 125 rpm to about 175 rpm. In some embodiments, forming the first mixture in Step a) is conducted at a stir rate of about 150 rpm. Step b) - Heating the First Mixture to a First Heating Temperature to form a Second Mixture. In some embodiments, the first heating temperature is about 20°C to about 85°C. In some embodiments, the first heating temperature is about 20°C to about 83°C. In some embodiments, the first heating temperature is about 20°C to about 55°C. In some embodiments, the first heating temperature is about 25°C to about 45°C. In some embodiments, the first heating temperature is about 50°C to about 83°C. In some embodiments, the first heating temperature is about 60°C to about 80°C. In some embodiments, the first heating temperature is about 70°C to about 80°C. In some embodiments, the first heating temperature is about 79°C to about 85°C. In some embodiments, an optional amount of <com:Math><semantics>H2O<annotation encoding="application / x-tex">H_2O< / annotation>< / semantics>< / com:Math> is added to the second mixture. In some embodiments, when water is added to the second mixture, the weight amount of water added is about 0.4 to about 2.3 times the weight of L-arginine originally added in forming the first mixture. In some embodiments, when water is added to the second mixture, the weight amount of water added is about 1.0:1.6 to about 1.0:2.1 times the weight of L-arginine originally added in forming the first mixture. In some embodiments, when water is added to the second mixture, the weight amount of water added is about 1.0:0.8 to about 1.0:1.9 times the weight of L-arginine originally added in forming the first mixture. In some embodiments, when water is added to the second mixture, the weight amount of water added is about 1.0:1.0 to about 1.0:1.7 times the weight of L-arginine originally added in forming the first mixture. In some embodiments, when water is added to the second mixture, the weight amount of water added is about 1.0:1.1 to about 1.0:1.6 times the weight of L-arginine originally added in forming the first mixture. In some embodiments, when water is added to the second mixture, the weight amount of water added is about 1.0:1.2 to about 1.0:1.5 times the weight of L-arginine originally added in forming the first mixture. In some embodiments, the second mixture is substantially a homogeneous solution. In some embodiments, Step b) is conducted at a stir rate of about 100 rpm to about 200 rpm. In some embodiments, Step b) is conducted at a stir rate of about 125 rpm to about 175 rpm. In some embodiments, Step b) is conducted at a stir rate of about 150 rpm. Step c) - Adding a First Additional Amount of the Water-Miscible Anti-Solvent to the Second Mixture while maintaining the First Heating Temperature to Form a Suspension. In some embodiments, the weight ratio of L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:5.46 to about 1.00:8.20. In some embodiments, the weight ratio of L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:4.70 to about 1.00:7.50. In some embodiments, the weight ratio of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:5.20 to about 1.00:7.00. In some embodiments, the weight ratio of L-arginine salt of (R)-2-(7-(4- cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:5.70 to about 1.00:6.50. In some embodiments, the weight ratio of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:5.90 to about 1.00:6.30. In some embodiments, the weight ratio of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−<annotation encoding="application / x-tex">(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:5.95 to about 1.00:6.25. In some embodiments, the weight ratio of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:6.00 to about 1.00:6.20. In some embodiments, the weight ratio of L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−cyclopentyl−3−<annotation encoding="application / x-tex">(R)-2-(7-(4-cyclopentyl-3-< / annotation>< / semantics>< / com:Math> (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to the first additional amount of 2-propanol is about 1.00:5.46 to about 1.00:8.20, about 1.00:5.81 to about 1.00:7.86, about 1.00:6.15 to about 1.00:7.51, about 1.00:6.28 to about 1.00:7.38, about 1.00:6.42 to about 1.00:7.24, about 1.00:6.56 to about 1.00:7.10, about 1.00:6.69 to about 1.00:6.97, or about 1.00:6.83. In some embodiments, the first additional amount of the water-miscible anti-solvent is added during a first time point and a second time point. In some embodiments, about 5% to about 15% of the first additional amount of the water- miscible anti-solvent is added at the first time point. In some embodiments, about 7% to about 13% of the first additional amount of the water-miscible anti-solvent is added at the first time point. In some embodiments, about 8% to about 12% of the first additional amount of the water-miscible anti-solvent is added at the first time point. In some embodiments, about 9% to about 11% of the first additional amount of the water-miscible anti-solvent is added at the first time point. In some embodiments, the first additional amount of the water-miscible anti-solvent is added at the first time point to form a cloudy mixture. In some embodiments, prior to the second time point, a seed crystal of L-arginine salt of (R)-2- (7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid is optionally added. In some embodiments, the first additional amount of the water-miscible anti-solvent is added at the second time point at a rate to complete the addition in about 1.00 hour or greater. In some embodiments, the first additional amount of the water-miscible anti-solvent is added at the second time point at a rate to complete the addition in about 1.00 hour to about 6.00 hours. In some embodiments, the first additional amount of the water-miscible anti-solvent is added at the second time point at a rate to complete the addition in about 1.00 hour to about 5.00 hours. In some embodiments, the first additional amount of the water-miscible anti-solvent is added at the second time point at a rate to complete the addition in about 1.00 hour to about 4.00 hours. In some embodiments, the first additional amount of the water-miscible anti-solvent is added at the second time point at a rate to complete the addition in about 1.00 hour to about 3.00 hours. In some embodiments, the first additional amount of the water-miscible anti-solvent is added at the second time point at a rate to complete the addition in about 1.00 hour to about 2.00 hours. In some embodiments, the first heating temperature is maintained during the addition of the first additional amount of 2-propanol to the second mixture. In some embodiments, Step c) is conducted at a stir rate of about 100 rpm to about 200 rpm. In some embodiments, Step c) is conducted at a stir rate of about 125 rpm to about 175 rpm. In some embodiments, Step c) is conducted at a stir rate of about 150 rpm. Step d) - Cooling the Suspension to a First Cooling Temperature and Thereafter Heating to a Second Heating Temperature. In some embodiments, cooling the suspension to the first cooling temperature in Step d) is conducted at a rate of about 8.80°C / hour to about 14.40°C / hour. In some embodiments, cooling the suspension to the first cooling temperature in Step d) is conducted at a rate of about 9.35°C / hour to about 13.80°C / hour. In some embodiments, cooling the suspension to the first cooling temperature in Step d) is conducted at a rate of about 9.90°C / hour to about 13.20°C / hour. In some embodiments, cooling the suspension to the first cooling temperature in Step d) is conducted at a rate of about 10.45°C / hour to about 12.60°C / hour. In some embodiments, cooling the suspension to the first cooling temperature in Step d) is conducted at a rate of about 10°C / hour to about 12°C / hour. In some embodiments, cooling the suspension to the first cooling temperature in Step d) is conducted at a rate of about 9°C / hour to about 11°C / hour. In some embodiments, cooling the suspension to the first cooling temperature in Step d) is conducted at a rate of about 9.5°C / hour to about 10.5°C / hour. In some embodiments, the first cooling temperature in Step d) is about 15°C to about 40°C. In some embodiments, the first cooling temperature in Step d) is about 20°C to about 30°C. In some embodiments, the first cooling temperature in Step d) is about 22°C to about 24°C. In some embodiments, the first cooling temperature in Step d) is about 18°C to about 22°C. In some embodiments, the first cooling temperature is maintained for at least 1 hour prior to heating to the second heating temperature. In some embodiments, the second heating temperature in Step d) is about 65°C to about 83°C. In some embodiments, the second heating temperature in Step d) is about 70°C to about 80°C. In some embodiments, the second heating temperature in Step d) is about 70°C to about 75°C. In some embodiments, the second heating temperature in Step d) is about 69°C to about 73°C. In some embodiments, after heating to the second heating temperature, the second heating temperature is maintained for at least 30 minutes. In some embodiments, Step d) is conducted at a stir rate of about 100 rpm to about 200 rpm. In some embodiments, Step d) is conducted at a stir rate of about 125 rpm to about 175 rpm. In some embodiments, Step d) is conducted at a stir rate of about 150 rpm. Step e) – Cycling Step d) Optionally One or More Times. It is understood that when cycling Step d) more than once that the first cooling temperature at each cycle may be the same or different and the second heating temperature at each cycle may be the same or different. Two Cycles In some embodiments, the cycling in Step e) comprises the cycling Step d) two times. In some embodiments, cycling Step d) two times comprises cooling the suspension to a first cycling cooling temperature, heating the suspension to a first cycling heating temperature, cooling the suspension to a second cycling cooling temperature, and heating the suspension to a second cycling heating temperature. In some embodiments, the first cycling cooling temperature is about 16°C to about 26°C, the first heating cycling temperature is about 55°C to about 65°C, the second cycling cooling temperature is about 26°C to about 36°C, and the second cycling heating temperature is about 45°C to about 55°C. In some embodiments, the first cycling cooling temperature is about 19°C to about 23°C, the first heating cycling temperature is about 58°C to about 62°C, the second cycling cooling temperature is about 29°C to about 33°C, and the second cycling heating temperature is about 48°C to about 52°C. In some embodiments, cooling to each cooling temperature is conducted at a substantially different cooling rate. In some embodiments, cooling to each cooling temperature is conducted at a different cooling rate. In some embodiments, the cycling in Step e) comprises the cycling Step d) two times. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 10.0°C / hour to about 15.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 11.0°C / hour to about 14.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 12.0°C / hour to about 13.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 12.5°C / hour. In some embodiments, the cycling in Step e) comprises the cycling Step d) two times. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 7.5°C / hour to about 12.5°C / hour. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 8.5°C / hour to about 11.5°C / hour. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 9.5°C / hour to about 10.5°C / hour. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 10.0°C / hour. Three Cycles In some embodiments, the cycling in Step e) comprises the cycling Step d) three times. In some embodiments, cycling Step d) three times comprises: cooling the suspension to a first cycling cooling temperature, heating the suspension to a first cycling heating temperature, cooling the suspension to a second cycling cooling temperature, heating the suspension to a second cycling heating temperature, cooling the suspension to a third cycling cooling temperature, and heating the suspension to a third cycling heating temperature. In some embodiments, the first cycling cooling temperature is about 16°C to about 26°C, the first heating cycling temperature is about 66°C to about 76°C, the second cycling cooling temperature is about 16°C to about 26°C, the second cycling heating temperature is about 55°C to about 65°C, the third cycling cooling temperature is about 26°C to about 36°C, and the third cycling heating temperature is about 45°C to about 55°C. In some embodiments, the first cycling cooling temperature is about 19°C to about 23°C, the first heating cycling temperature is about 69°C to about 73°C, the second cycling cooling temperature is about 19°C to about 23°C, the second cycling heating temperature is about 58°C to about 62°C, the third cycling cooling temperature is about 29°C to about 33°C, and the third cycling heating temperature is about 48°C to about 52°C. In some embodiments, cooling to each cooling temperature is conducted at a substantially different cooling rate. In some embodiments, cooling to each cooling temperature is conducted at a different cooling rate. In some embodiments, cooling to the first cycling cooling temperature and the second cycling cooling temperature are each conducted at substantially the same cooling rate. In some embodiments, the cycling in Step e) comprises the cycling Step d) three times. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 10.0°C / hour to about 15.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 11.0°C / hour to about 14.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 12.0°C / hour to about 13.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 12.5°C / hour. In some embodiments, the cycling in Step e) comprises the cycling Step d) three times. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 10.0°C / hour to about 15.0°C / hour. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 11.0°C / hour to about 14.0°C / hour. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 12.0°C / hour to about 13.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 12.5°C / hour. In some embodiments, the cycling in Step e) comprises the cycling Step d) three times. In some embodiments, cooling to the third cycling cooling temperature is conducted at a rate of about 7.5°C / hour to about 12.5°C / hour. In some embodiments, cooling to the third cycling cooling temperature is conducted at a rate of about 8.5°C / hour to about 11.5°C / hour. In some embodiments, cooling to the third cycling cooling temperature is conducted at a rate of about 9.5°C / hour to about 10.5°C / hour. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 10.0°C / hour. Four Cycles In some embodiments, the cycling in Step e) comprises the cycling Step d) four times. In some embodiments, cycling Step d) four times comprises: cooling the suspension to a first cycling cooling temperature, heating the suspension to a first cycling heating temperature, cooling the suspension to a second cycling cooling temperature, heating the suspension to a second cycling heating temperature, cooling the suspension to a third cycling cooling temperature, heating the suspension to a third cycling heating temperature, cooling the suspension to a fourth cycling cooling temperature, and heating the suspension to a fourth cycling heating temperature. In some embodiments, the first cycling cooling temperature is about 16°C to about 26°C, the first heating cycling temperature is about 66°C to about 76°C, the second cycling cooling temperature is about 16°C to about 26°C, the second cycling heating temperature is about 66°C to about 76°C, the third cycling cooling temperature is about 16°C to about 26°C, the third cycling heating temperature is about 55°C to about 65°C, the fourth cycling cooling temperature is about 26°C to about 36°C, and the fourth cycling heating temperature is about 45°C to about 55°C. In some embodiments, the first cycling cooling temperature is about 19°C to about 23°C, the first heating cycling temperature is about 69°C to about 73°C, the second cycling cooling temperature is about 19°C to about 23°C, the second cycling heating temperature is about 69°C to about 73°C, the third cycling cooling temperature is about 19°C to about 23°C, the third cycling heating temperature is about 58°C to about 62°C, the fourth cycling cooling temperature is about 29°C to about 33°C, and the fourth cycling heating temperature is about 48°C to about 52°C. In some embodiments, cooling to each cooling temperature is conducted at a substantially different cooling rate. In some embodiments, cooling to each cooling temperature is conducted at a different cooling rate. In some embodiments, cooling to the first cycling cooling temperature, the second cycling cooling temperature, and the third cycling cooling temperature are each conducted at substantially the same cooling rate. In some embodiments, the cycling in Step e) comprises the cycling Step d) four times. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 10.0°C / hour to about 15.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 11.0°C / hour to about 14.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 12.0°C / hour to about 13.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 12.5°C / hour. In some embodiments, the cycling in Step e) comprises the cycling Step d) four times. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 10.0°C / hour to about 15.0°C / hour. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 11.0°C / hour to about 14.0°C / hour. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 12.0°C / hour to about 13.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 12.5°C / hour. In some embodiments, the cycling in Step e) comprises the cycling Step d) four times. In some embodiments, cooling to the third cycling cooling temperature is conducted at a rate of about 10.0°C / hour to about 15.0°C / hour. In some embodiments, cooling to the third cycling cooling temperature is conducted at a rate of about 11.0°C / hour to about 14.0°C / hour. In some embodiments, cooling to the third cycling cooling temperature is conducted at a rate of about 12.0°C / hour to about 13.0°C / hour. In some embodiments, cooling to the first cycling cooling temperature is conducted at a rate of about 12.5°C / hour. In some embodiments, the cycling in Step e) comprises the cycling Step d) four times. In some embodiments, cooling to the fourth cycling cooling temperature is conducted at a rate of about 7.5°C / hour to about 12.5°C / hour. In some embodiments, cooling to the fourth cycling cooling temperature is conducted at a rate of about 8.5°C / hour to about 11.5°C / hour. In some embodiments, cooling to the fourth cycling cooling temperature is conducted at a rate of about 9.5°C / hour to about 10.5°C / hour. In some embodiments, cooling to the second cycling cooling temperature is conducted at a rate of about 10.0°C / hour. In some embodiments, Step e) is conducted at a stir rate of about 100 rpm to about 200 rpm. In some embodiments, Step e) is conducted at a stir rate of about 125 rpm to about 175 rpm. In some embodiments, Step e) is conducted at a stir rate of about 150 rpm. Step f) - Cooling the Suspension to a Final Cooling Temperature to Form the Crystalline Free-Plate Habit of L-Arginine Salt of (R)-2-(7-(4-Cyclopentyl-3-(trifluoromethyl)benzyloxy)- 1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic Acid. In some embodiments, cooling the suspension in Step f) is conducted at a rate of about 7.5°C / hour to about 12.5°C / hour. In some embodiments, cooling the suspension in Step f) is conducted at a rate of about 8.5°C / hour to about 11.5°C / hour. In some embodiments, cooling the suspension in Step f) is conducted at a rate of about 9.5°C / hour to about 10.5°C / hour. In some embodiments, cooling the suspension in Step f) is conducted at a rate of about 10.0°C / hour. In some embodiments, cooling the suspension in Step f) is conducted at a rate of about 8.8°C / hour to about 14.4°C / hour. In some embodiments, cooling the suspension in Step f) is conducted at a rate of about 9.4°C / hour to about 13.8°C / hour. In some embodiments, cooling the suspension in Step f) is conducted at a rate of about 9.9°C / hour to about 13.2°C / hour. In some embodiments, cooling the suspension in Step f) is conducted at a rate of about 10.5°C / hour to about 12.6°C / hour. In some embodiments, cooling the suspension in Step f) is conducted at a rate of about 10°C / hour to about 12°C / hour. In some embodiments, after cooling in Step f) the temperature of the suspension is about 15°C to about 40°C. In some embodiments, after cooling in Step f) the temperature of the suspension is about 20°C to about 30°C. In some embodiments, after cooling in Step f) the temperature of the suspension is about 22°C to about 24°C. In some embodiments, after cooling in Step f) the temperature of said suspension is about 18°C to about 22°C. In some embodiments, Step f) is conducted at a stir rate of about 100 rpm to about 200 rpm. In some embodiments, Step f) is conducted at a stir rate of about 125 rpm to about 175 rpm. In some embodiments, Step f) is conducted at a stir rate of about 150 rpm. In some embodiments, the method further comprises the step of isolating the crystalline free- plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−(trifluoromethyl)benzyloxy)−1,2,3,4−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-< / annotation>< / semantics>< / com:Math> tetrahydrocyclopenta[b]indol-3-yl)acetic acid. In some embodiments, the step of isolating comprises filtering the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−(trifluoromethyl)benzyloxy)−1,2,3,4−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-< / annotation>< / semantics>< / com:Math> tetrahydrocyclopenta[b]indol-3-yl)acetic acid from the suspension. In some embodiments, the step of isolating comprises filtering the crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)−2−(7−(4−<annotation encoding="application / x-tex">(R)-2-(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid from the suspension and drying the crystalline free-plate habit of L-arginine salt at a reduced pressure. In some embodiments, after filtering, the crystalline free-plate habit of L-arginine salt of (R)-2- (7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid has any one or more of the characteristics as described herein. Another aspect of the present invention relates to pharmaceutical compositions prepared according to any of the methods as described herein. Another aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)acetic acid prepared according to any of the methods as described herein. A composition comprising a crystalline free-plate habit of L-arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−<annotation encoding="application / x-tex">(7-(4-< / annotation>< / semantics>< / com:Math> cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid prepared according to any of the methods as described herein. A pharmaceutical composition comprising a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3- yl)acetic acid prepared according to any of the methods as described herein and a pharmaceutical excipient. In some embodiments, the pharmaceutical composition is suitable for oral, rectal, nasal, topical, buccal, sub-lingual, or vaginal, or in a form suitable for administration by inhalation, insufflation, or by a transdermal patch. In some embodiments, the pharmaceutical composition is suitable for oral administration. CRYSTALLINE PLATE HABIT OR MORPHOLOGY The present invention is directed, inter alia, to a crystalline free-plate habit or morphology and processes useful in the preparation of a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4- cyclopentyl-3-(trifluoromethyl)-benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. The plates were discovered from the novel synthetic methods as described herein and were shown to be thin hexagonal-like plates with two opposite sides of the plate being longer that the other sides (i.e., elongated hexagonal plate). However, due to the thin characteristic of the plates, a complete unbroken plate is rarely seen. Instead, what is generally observed are large to small broken pieces of the thin hexagonal-like plates. Figure 5B shows a copy of Figure 5A that has been modified to add an outline to highlight the substantially intact / complete free-plate with an elongated hexagonal shape. It is understood by those skilled in the art that microscopy is one of the more useful techniques to distinguish two crystalline habits or morphologies. This is particularly useful when 2 or more morphologies are associated with the same or substantially the same crystal phase as is the case with the L-arginine salt of Compound 1. Comparing the PXRD patterns of the habit prepared previously (i.e., WO2011 / 094008 and Example 2 infra) and the plate habit prepared as described herein (i.e., see Figure 19, PXRD overlay between spherulites and plates) it was observed that the two PXRD patterns were the same or substantially the same, thus the two habits represent the same crystal phase. Although the two habits revealed the same or substantially the same PXRD pattern, a higher degree of crystallinity was observed for the plate habit as indicated in Figure 19 by substantially higher peak intensities and yet lower sample-related background scatter (i.e., a lower amorphous halo contribution). Since sample size and sample preparation can affect peak intensities and sample-related background scatter, and since the two habits share the same crystal phase, PXRD may not be considered the most appropriate test method to distinguish between two habits. However, PXRD does allow for determining whether two habits have the same crystal phase or different crystal phases. For determining different habits, microscopy is one of the more useful methods. Accordingly, the skilled person would be capable of reviewing a micrograph for a crystal habit prepared by the processes described herein and readily acknowledge that the crystal habit was a free-plate or pieces resulting from a broken free-plate and not some other habit, such as, what was prepared previously in the art. Similarly, by simple inspection of two micrographs, such as Figure 1 (spherulites) and Figure 5A (free-plates), one can readily confirm they are different habits. In addition to the techniques described hererin, specific surface can also be used to characterize the free-plates of the present invention. Accordingly, the specific surface area values disclosed in the present invention have been obtained by means of a specific surface area analysis technique based on the BET (Brunauer, Emmett and Teller) theory, which is a well-accepted theory known in the art for the calculation of surface areas of solids by means of measuring their physical adsorption of gas molecules (see: Brunauer, S.; Emmett, P. H.; and Teller, E.; J. Am. Chem. Soc., 1938, 60, 309). In particular, the specific surface area values measured in the present invention have been calculated from the BET surface area plot obtained by measuring the quantity of nitrogen gas molecules adsorbed by a weighted amount of solid at different relative pressures <com:Math><semantics>(P / P0)<annotation encoding="application / x-tex">(P / P_0)< / annotation>< / semantics>< / com:Math> within the range 0.05-0.3 <com:Math><semantics>(P / P0)<annotation encoding="application / x-tex">(P / P_0)< / annotation>< / semantics>< / com:Math>, at 77.3 K. The measurement of the adsorption of gas molecules was carried out by means of a Micromeritics TM TriStar II BET surface analyzer having the characteristics as set out below in Example 14. Namely, nitrogen gas was used for the adsorption measurement. The sample for each analysis was degassed at 25°C for 960 minutes under vacuum (i.e., 100 mm / Hg). The determination of the adsorption of nitrogen was measured at 77.3 K at eleven relative pressures (P / P<com:Sub>0< / com:Sub>) sufficiently dispersed within the range of about 0.05 to about 0.30 (i.e. eleven absolute pressures in the range of about 36 mm Hg to about 223 mm Hg relative to the saturated pressure at the time of measurement that ranged from about 738 mmHg to about 743 mmHg). One aspect of the present invention relates to a novel crystalline plate morphology of L- arginine salt of <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>-2-<com:Math><semantics>(7−(4−cyclopentyl−3−(trifluoromethyl)benzyloxy)−1,2,3,4−tetrahydrocyclo−<annotation encoding="application / x-tex">(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-< / annotation>< / semantics>< / com:Math> penta[b]indol-3-yl)acetic acid as described herein. One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘<annotation encoding="application / x-tex">20.5^{\circ}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> 0.2°, and 24.6° <com:Math><semantics>±<annotation encoding="application / x-tex">\pm< / annotation>< / semantics>< / com:Math> 0.2°. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2∘<annotation encoding="application / x-tex">0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>28.8∘±0.2∘<annotation encoding="application / x-tex">28.8^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2∘<annotation encoding="application / x-tex">0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>28.8∘±0.2∘<annotation encoding="application / x-tex">28.8^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>37.3∘±0.2∘<annotation encoding="application / x-tex">37.3^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.0°C to 208.5°C at a scan rate of 10°C / minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.0°C to 208.1°C at a scan rate of 10°C / minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°C to 208.5°C at a scan rate of 10°C / minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 206.0°C to 208.5°C at a scan rate of 10°C / minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 206.5°C to 208.5°C at a scan rate of 10°C / minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°C to 208.1°C at a scan rate of 10°C / minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 206.5°C to 208.1°C at a scan rate of 10°C / minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 207.0°C to 208.1°C at a scan rate of 10°C / minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace conducted at a scan rate of 10°C / minute comprising an endotherm substantially as depicted in any one of Figures 6 to 10. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace conducted at a scan rate of 10°C / minute comprising an endotherm substantially as depicted in any one of Figures 6 to 10 and Figures 22 to 25. In some embodiments, the crystalline free-plate habit has a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.3% weight or less at 90% RH. In some embodiments, the crystalline free-plate habit has a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.2% weight or less at 90% RH. One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid having a BET specific surface area of about 0.05 m<com:Sup>2< / com:Sup> / g, about 0.1 m<com:Sup>2< / com:Sup> / g, about 0.15 m<com:Sup>2< / com:Sup> / g, about 0.2 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">m^2 / g< / annotation>< / semantics>< / com:Math>, about 0.25 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">m^2 / g< / annotation>< / semantics>< / com:Math>, about 0.3 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">m^2 / g< / annotation>< / semantics>< / com:Math>, about 0.35 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">m^2 / g< / annotation>< / semantics>< / com:Math>, about 0.4 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">m^2 / g< / annotation>< / semantics>< / com:Math>, about 0.45 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">m^2 / g< / annotation>< / semantics>< / com:Math>, about 0.5 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">m^2 / g< / annotation>< / semantics>< / com:Math>, about 0.55 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">m^2 / g< / annotation>< / semantics>< / com:Math>, about 0.6 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">m^2 / g< / annotation>< / semantics>< / com:Math>, about 0.65 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">m^2 / g< / annotation>< / semantics>< / com:Math>, or about 0.7 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">m^2 / g< / annotation>< / semantics>< / com:Math> to about 2.0 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">m^2 / g< / annotation>< / semantics>< / com:Math>, about 2.5 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">m^2 / g< / annotation>< / semantics>< / com:Math>, about 3.0 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">m^2 / g< / annotation>< / semantics>< / com:Math>, about 3.5 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">m^2 / g< / annotation>< / semantics>< / com:Math>, about 4.0 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">m^2 / g< / annotation>< / semantics>< / com:Math>, about 4.5 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">m^2 / g< / annotation>< / semantics>< / com:Math>, about 5.0 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">m^2 / g< / annotation>< / semantics>< / com:Math>, about 5.5 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">m^2 / g< / annotation>< / semantics>< / com:Math>, about 6.0 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">\text{m}^2 / \text{g}< / annotation>< / semantics>< / com:Math>, about 6.5 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">\text{m}^2 / \text{g}< / annotation>< / semantics>< / com:Math>, about 7.0 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">\text{m}^2 / \text{g}< / annotation>< / semantics>< / com:Math>, about 7.5 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">\text{m}^2 / \text{g}< / annotation>< / semantics>< / com:Math>, about 8.0 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">\text{m}^2 / \text{g}< / annotation>< / semantics>< / com:Math>, about 8.5 <com:Math><semantics>m2 / g<annotation encoding="application / x-tex">\text{m}^2 / \text{g}< / annotation>< / semantics>< / com:Math>, about <com:Math><semantics>9.0 m2 / g<annotation encoding="application / x-tex">9.0 \text{ m}^2 / \text{g}< / annotation>< / semantics>< / com:Math>, or about <com:Math><semantics>9.5 m2 / g<annotation encoding="application / x-tex">9.5 \text{ m}^2 / \text{g}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.1 m<com:Sup>2< / com:Sup> / g to about 5.0 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.1 m<com:Sup>2< / com:Sup> / g to about 4.0 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.3 m<com:Sup>2< / com:Sup> / g to about 4.0 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.5 m<com:Sup>2< / com:Sup> / g to about 4.0 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.6 m<com:Sup>2< / com:Sup> / g to about 4.0 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.3 m<com:Sup>2< / com:Sup> / g to about 3.0 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.4 m<com:Sup>2< / com:Sup> / g to about 2.0 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.5 m<com:Sup>2< / com:Sup> / g to about 1.8 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.6 m<com:Sup>2< / com:Sup> / g to about 1.6 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has: 1) a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2∘<annotation encoding="application / x-tex">0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>28.8∘±0.2∘<annotation encoding="application / x-tex">28.8^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>37.3∘±0.2∘<annotation encoding="application / x-tex">37.3^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>; 2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.0°C to 208.5°C at a scan rate of 10°C / minute; and / or 3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.3% weight or less at 90% RH. In some embodiments, the crystalline free-plate habit has: 1) a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2∘<annotation encoding="application / x-tex">0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>; 2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 206.5°C to t 208.5°C at a scan rate of 10°C / minute; and / or 3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.3% weight or less at 90% RH. In some embodiments, the crystalline free-plate habit has: 1) a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±<annotation encoding="application / x-tex">20.5^{\circ} \pm< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2∘<annotation encoding="application / x-tex">0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>; 2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°C to 208.5°C at a scan rate of 10°C / minute; and / or 3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.2% weight or less at 90% RH. In some embodiments, the crystalline free-plate habit has: 1) a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±10.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 10.2^{\circ}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2∘<annotation encoding="application / x-tex">0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>; 2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 207.1°C to 208.1°C at a scan rate of 10°C / minute; and / or 3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.2% weight or less at 90% RH. In some embodiments, the crystalline free-plate habit has: 1) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.0°C to 208.5°C at a scan rate of 10°C / minute; and / or 2) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.3% weight or less at 90% RH. In some embodiments, the crystalline free-plate habit has: 1) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 206.5°C to t 208.5°C at a scan rate of 10°C / minute; and / or 2) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.3% weight or less at 90% RH. In some embodiments, the crystalline free-plate habit has: 1) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°C to 208.5°C at a scan rate of 10°C / minute; and / or 2) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.2% weight or less at 90% RH. In some embodiments, the crystalline free-plate habit has: 1) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 207.1°C to 208.1°C at a scan rate of 10°C / minute; and / or 2) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.2% weight or less at 90% RH. In some embodiments, the crystalline free-plate habit has: 1) a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2∘<annotation encoding="application / x-tex">0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>; 2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.0°C to 208.5°C at a scan rate of 10°C / minute; 3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.3% weight or less at 90% RH; and / or 4) a BET specific surface area of about 0.1 m<com:Sup>2< / com:Sup> / g to about 5.0 m<com:Sup>2< / com:Sup> / g.In some embodiments, the crystalline free-plate habit has: 1) a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±<annotation encoding="application / x-tex">20.5^{\circ} \pm< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2∘<annotation encoding="application / x-tex">0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>; 2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°C to t 208.5°C at a scan rate of 10°C / minute; 3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.3% weight or less at 90% RH; and / or 4) a BET specific surface area of about 0.1 m<com:Sup>2< / com:Sup> / g to about 4.0 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has: 1) a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±<annotation encoding="application / x-tex">20.5^{\circ} \pm< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2∘<annotation encoding="application / x-tex">0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>; 2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°C to t 208.5°C at a scan rate of 10°C / minute; 3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.3% weight or less at 90% RH; and / or 4) a BET specific surface area of about 0.3 m<com:Sup>2< / com:Sup> / g to about 3.0 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has: 1) a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±10.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 10.2^{\circ}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2∘<annotation encoding="application / x-tex">0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>; 2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°C to 208.5°C at a scan rate of 10°C / minute; 3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.3% weight or less at 90% RH; and / or 4) a BET specific surface area of about 0.6 m<com:Sup>2< / com:Sup> / g to about 4.0 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has: 1) a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2∘<annotation encoding="application / x-tex">0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>; 2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 206.5°C to t 208.5°C at a scan rate of 10°C / minute; 3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.3% weight or less at 90% RH; and / or 4) a BET specific surface area of about 0.4 m<com:Sup>2< / com:Sup> / g to about 2.0 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has: 1) a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2∘<annotation encoding="application / x-tex">0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>28.8∘±0.2∘<annotation encoding="application / x-tex">28.8^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>; 2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 206.5°C to 208.1°C at a scan rate of 10°C / minute; 3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.2% weight or less at 90% RH; and / or 4) a BET specific surface area of about 0.5 m<com:Sup>2< / com:Sup> / g to about 1.8 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has: 1) a powder X-ray diffraction pattern comprising peaks, in terms of 20, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±10.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 10.2^{\circ}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2∘<annotation encoding="application / x-tex">0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>28.8∘±0.2∘<annotation encoding="application / x-tex">28.8^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>37.3∘±0.2∘<annotation encoding="application / x-tex">37.3^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>; 2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°C to 208.1°C at a scan rate of 10°C / minute; 3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.2% weight or less at 90% RH; and / or 4) a BET specific surface area of about 0.6 m2 / g to about 4.0 m2 / g. In some embodiments, the crystalline free-plate habit has: 1) a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2∘<annotation encoding="application / x-tex">0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>28.8∘±0.2∘<annotation encoding="application / x-tex">28.8^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>37.3∘±0.2∘<annotation encoding="application / x-tex">37.3^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>; 2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 207.1°C to 208.1°C at a scan rate of 10°C / minute; 3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.2% weight or less at 90% RH; and / or 4) a BET specific surface area of about 0.6 m<com:Sup>2< / com:Sup> / g to about 1.6 m<com:Sup>2< / com:Sup> / g. One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid having a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±<annotation encoding="application / x-tex">16.4^{\circ} \pm< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2∘<annotation encoding="application / x-tex">0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>28.8∘±0.2∘<annotation encoding="application / x-tex">28.8^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>28.8∘±0.2∘<annotation encoding="application / x-tex">28.8^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>37.3∘±0.2∘<annotation encoding="application / x-tex">37.3^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid having a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.0°C to 208.5°C when scanned at 10°C per minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.0°C to 208.1°C at a scan rate of 10°C / minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°C to 208.5°C at a scan rate of 10°C / minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°C to 208.1°C at a scan rate of 10°C / minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 206.0°C to 208.5°C at a scan rate of 10°C / minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 206.5°C to 208.5°C at a scan rate of 10°C / minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 206.5°C to 208.1°C at a scan rate of 10°C / minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 207.0°C to 208.1°C at a scan rate of 10°C / minute. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace conducted at a scan rate of 10°C / minute comprising an endotherm substantially as depicted in any one of Figures 6 to 10. In some embodiments, the crystalline free-plate habit has a differential scanning calorimetry trace conducted at a scan rate of 10°C / minute comprising an endotherm substantially as depicted in any one of Figures 6 to 10 and Figures 22 to 25. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and 20.5° ± 0.2°. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>28.8∘±0.2∘<annotation encoding="application / x-tex">28.8^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 20, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>28.8∘±0.2∘<annotation encoding="application / x-tex">28.8^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>37.3∘±0.2∘<annotation encoding="application / x-tex">37.3^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid having a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.3% weight or less at 90% RH. In some embodiments, the crystalline free-plate habit has a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein the crystalline free-plate habit gains about 0.2% weight or less at 90% RH. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±<annotation encoding="application / x-tex">16.4^{\circ} \pm< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2∘<annotation encoding="application / x-tex">0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>28.8∘±0.2∘<annotation encoding="application / x-tex">28.8^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>28.8∘±0.2∘<annotation encoding="application / x-tex">28.8^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>37.3∘±0.2∘<annotation encoding="application / x-tex">37.3^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. One aspect of the present invention relates to a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid having a BET specific surface area of about 0.1 m<com:Sup>2< / com:Sup> / g to about 5.0 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.1 m<com:Sup>2< / com:Sup> / g to about 4.0 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.3 m<com:Sup>2< / com:Sup> / g to about 4.0 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.5 m<com:Sup>2< / com:Sup> / g to about 4.0 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.6 m<com:Sup>2< / com:Sup> / g to about 4.0 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.3 m<com:Sup>2< / com:Sup> / g to about 3.0 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.4 m<com:Sup>2< / com:Sup> / g to about 2.0 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.5 m<com:Sup>2< / com:Sup> / g to about 1.8 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has a BET specific surface area of about 0.6 m<com:Sup>2< / com:Sup> / g to about 1.6 m<com:Sup>2< / com:Sup> / g. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±<annotation encoding="application / x-tex">16.4^{\circ} \pm< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.2∘<annotation encoding="application / x-tex">0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>28.8∘±0.2∘<annotation encoding="application / x-tex">28.8^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. In some embodiments, the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of <com:Math><semantics>2θ<annotation encoding="application / x-tex">2\theta< / annotation>< / semantics>< / com:Math>, at <com:Math><semantics>8.2∘±0.2∘<annotation encoding="application / x-tex">8.2^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>16.4∘±0.2∘<annotation encoding="application / x-tex">16.4^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>20.5∘±0.2∘<annotation encoding="application / x-tex">20.5^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>24.6∘±0.2∘<annotation encoding="application / x-tex">24.6^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>28.8∘±0.2∘<annotation encoding="application / x-tex">28.8^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>37.3∘±0.2∘<annotation encoding="application / x-tex">37.3^{\circ} \pm 0.2^{\circ}< / annotation>< / semantics>< / com:Math>. INDICATIONS S1P receptor agonists having agonist activity on the S1P<com:Sub>1< / com:Sub> receptor have been shown to rapidly and reversibly induce lymphopenia (also referred to as peripheral lymphocyte lowering (PLL); Hale et al., Bioorg. Med. Chem. Lett., 14:3351-3355, 2004). This is attended by clinically useful immunosuppression by virtue of sequestering T- and B-cells in secondary lymphoid tissue (lymph nodes and Peyer's patches) and thus apart from sites of inflammation and organ grafts (Rosen et al., Immunol. Rev., 195:160-177, 2003; Schwab et al., Nature Immunol., 8:1295-1301, 2007). This lymphocyte sequestration, for example in lymph nodes, is thought to be a consequence of concurrent agonist-driven functional antagonism of the S1P<com:Sub>1< / com:Sub> receptor on T-cells (whereby the ability of S1P to mobilize T-cell egress from lymph nodes is reduced) and persistent agonism of the S1P<com:Sub>1< / com:Sub> receptor on lymph node endothelium (such that barrier function opposing transmigration of lymphocytes is increased) (Matloubian et al., Nature, 427:355-360, 2004; Baumruker et al., Expert Opin. Investig. Drugs, 16:283-289, 2007). It has been reported that agonism of the S1P<com:Sub>1< / com:Sub> receptor alone is sufficient to achieve lymphocyte sequestration (Sanna et al., J Biol Chem., 279:13839-13848, 2004) and that this occurs without impairment of immune responses to systemic infection (Brinkmann et al., Transplantation, 72:764-769, 2001; Brinkmann et al., Transplant Proc., 33:530-531, 2001). That agonism of endothelial S1P<com:Sub>1< / com:Sub> receptors has a broader role in promoting vascular integrity is supported by work implicating the S1P<com:Sub>1< / com:Sub> receptor in capillary integrity in mouse skin and lung (Sanna et al., Nat Chem Biol., 2:434-441, 2006). Vascular integrity can be compromised by inflammatory processes, for example as may derive from sepsis, major trauma and surgery so as to lead to acute lung injury or respiratory distress syndrome (Johan Groeneveld, Vascul. Pharmacol., 39:247-256, 2003). An exemplary S1P receptor agonist having agonist activity on the S1P<com:Sub>1< / com:Sub> receptor is FTY720, an immunosuppressive agent (Martini et al., Expert Opin. Investig. Drugs, 16:505-518, 2007) that was approved by the FDA as Gilenya® (fingolimod) in September 2010 for the treatment of relapsing multiple sclerosis. FTY720 acts as a prodrug which is phosphorylated in vivo; the phosphorylated derivative is an agonist for S1P<com:Sub>1< / com:Sub>, S1P<com:Sub>3< / com:Sub>, S1P<com:Sub>4< / com:Sub>, and S1P<com:Sub>5< / com:Sub> receptors (but not the S1P<com:Sub>2< / com:Sub> receptor) (Chiba, Pharmacology & Therapeutics, 108:308-319, 2005). FTY720 has been shown to rapidly and reversibly induce lymphopenia (also referred to as peripheral lymphocyte lowering (PLL); Hale et al., Bioorg. Med. Chem. Lett., 14:3351-3355, 2004). This is attended by clinically useful immunosuppression by virtue of sequestering T- and B-cells in secondary lymphoid tissue (lymph nodes and Peyer's patches) and thus apart from sites of inflammation and organ grafts (Rosen et al., Immunol. Rev., 195:160-177, 2003; Schwab et al., Nature Immunol., 8:1295-1301, 2007). FTY720 has been reported to have therapeutic efficacy in at least: a rat model for autoimmune myocarditis and a mouse model for acute viral myocarditis (Kiyabayashi et al., J. Cardiovasc. Pharmacol., 35:410-416, 2000; Miyamoto et al., J. Am. Coll. Cardiol., 37:1713-1718, 2001); mouse models for inflammatory bowel disease including colitis (Mizushima et al., Inflamm. Bowel Dis., 10:182-192, 2004; Deguchi et al., Oncology Reports, 16:699-703, 2006; Fujii et al., Am. J. Physiol. Gastrointest. Liver Physiol., 291:G267-G274, 2006; Daniel et al., J. Immunol., 178:2458-2468, 2007); a rat model for progressive mesangioproliferative glomerulonephritis (Martini et al., Am. J. Physiol. Renal Physiol., 292:F1761-F1770, 2007); a mouse model for asthma, suggested to be primarily through the S1P<com:Sub>1< / com:Sub> receptor on the basis of work using the S1P<com:Sub>1< / com:Sub> receptor agonist SEW2871 (Idzko et al, J. Clin. Invest., 116:2935-2944, 2006); a mouse model for airway inflammation and induction of bronchial hyperresponsiveness (Sawicka et al., J. Immunol., 171;6206-6214, 2003); a mouse model for atopic dermatitis (Kohno et al., Biol. Pharm. Bull., 27:1392-1396, 2004); a mouse model for ischemia- reperfusion injury (Kaudel et al., Transplant. Proc, 39:499-502, 2007); a mouse model for systemic lupus erythematosus (SLE) (Okazaki et al., J. Rheumatol., 29:707-716, 2002; Herzinger et al, Am. J. Clin. Dermatol., 8:329-336, 2007); rat models for rheumatoid arthritis (Matsuura et al., Int. J. Immunopharmacol., 22:323-331, 2000; Matsuura et al., Inflamm. Res., 49:404-410, 2000); a rat model for autoimmune uveitis (Kurose et al., Exp. Eye Res., 70:7-15, 2000); mouse models for type I diabetes (Fu et al, Transplantation, 73:1425-1430, 2002; Maki et al., Transplantation, 74:1684-1686, 2002; Yang et al., Clinical Immunology, 107:30-35, 2003; Maki et al., Transplantation, 79:1051-1055, 2005); mouse models for atherosclerosis (Nofer et al., Circulation, 115:501-508, 2007; Keul et al., Arterioscler. Thromb. Vasc. Biol., 27:607-613, 2007); a rat model for brain inflammatory reaction following traumatic brain injury (TBI) (Zhang et al., J. Cell. Mol. Med., 11:307-314, 2007); and mouse models for graft coronary artery disease and graft-versus-host disease (GVHD) (Hwang et al., Circulation, 100:1322-1329, 1999; Taylor et al., Blood, 110:3480-3488, 2007). In vitro results suggest that FTY720 may have therapeutic efficacy for β-amyloid-related inflammatory diseases including Alzheimer's disease (Kaneider et al., FASEB J., 18:309-311, 2004). KRP-203, an S1P receptor agonist having agonist activity on the S1P<com:Sub>1< / com:Sub> receptor, has been reported to have therapeutic efficacy in a rat model for autoimmune myocarditis (Ogawa et al., BBRC, 361:621-628, 2007). Using the S1P<com:Sub>1< / com:Sub> receptor agonist SEW2871, it has been shown that agonism of endothelial S1P<com:Sub>1< / com:Sub> receptors prevents proinflammatory monocyte / endothelial interactions in type I diabetic vascular endothelium (Whetzel et al., Circ. Res., 99:731-739, 2006) and protects the vasculature against TNFα-mediated monocyte / endothelial interactions (Bolick et al., Arterioscler. Thromb. Vasc. Biol., 25:976-981, 2005). Additionally, FTY720 has been reported to have therapeutic efficacy in experimental autoimmune encephalomyelitis (EAE) in rats and mice, a model for human multiple sclerosis (Brinkmann et al., J. Biol. Chem., 277:21453-21457, 2002; Fujino et al., J. Pharmacol. Exp. Ther., 305:70-77, 2003; Webb et al., J. Neuroimmunol., 153:108-121, 2004; Rausch et al., J. Magn. Reson. Imaging, 20:16-24, 2004; Kataoka et al., Cellular & Molecular Immunology, 2:439-448, 2005; Brinkmann et al., Pharmacology & Therapeutics, 115:84-105, 2007; Baumruker et al., Expert Opin. Investig. Drugs, 16:283-289, 2007; Balatoni et al., Brain Research Bulletin, 74:307-316, 2007). Furthermore, FTY720 has been found to have therapeutic efficacy for multiple sclerosis in clinical trials. In Phase II clinical trials for relapsing-remitting multiple sclerosis, FTY720 was found to reduce the number of lesions detected by magnetic resonance imaging (MRI) and clinical disease activity in patients with multiple sclerosis (Kappos et al., N. Engl. J. Med., 355:1124-1140, 2006; Martini et al., Expert Opin. Investig. Drugs, 16:505-518, 2007; Zhang et al., Mini-Reviews in Medicinal Chemistry, 7:845-850, 2007; Brinkmann, Pharmacology & Therapeutics, 115:84-105, 2007). FTY720 is currently in Phase III studies of remitting-relapsing multiple sclerosis (Brinkmann, Pharmacology & Therapeutics, 115:84-105, 2007; Baumruker et al., Expert. Opin. Investig. Drugs, 16:283-289, 2007; Dev et al., Pharmacology and Therapeutics, 117:77-93, 2008). FTY720 has also been reported to have anti-viral activity. Specific data has been presented in the lymphocytic choriomeningitis virus (LCMV) mouse model, wherein the mice were infected with either the Armstrong or the clone 13 strain of LCMV (Premenko-Lanier et al., Nature, 454, 894, 2008). FTY720 has also been reported to impair migration of dendritic cells infected with Francisella tularensis to the mediastinal lymph node, thereby reducing the bacterial colonization of it. Francisella tularensis is associated with tularemia, ulceroglandular infection, respiratory infection and a typhoidal disease (E. Bar-Haim et al., PLoS Pathog 4(11): e1000211. doi:10.1371 / journal.ppat.1000211, 2008). It has also been reported that a short-term high dose of FTY720 rapidly reduced ocular infiltrates in experimental autoimmune uveoretinitis. When given in the early stages of ocular inflammation, FTY720 rapidly prevented retinal damage. It was reported to not only prevent infiltration of target organs, but also reduce existing infiltration (Raveney et al., Arch. Ophthalmol. 126(10), 1390, 2008). It has been reported that treatment with FTY720 relieved ovariectomy-induced osteoporosis in mice by reducing the number of mature osteoclasts attached to the bone surface. The data provided evidence that S1P controlled the migratory behavior of osteoclast precursors, dynamically regulating bone mineral homeostasis (Ishii et al., Nature, 458(7237), 524–528, 2009). Agonism of the S1P<com:Sub>1< / com:Sub> receptor has been implicated in enhancement of survival of oligodendrocyte progenitor cells. Survival of oligodendrocyte progenitor cells is a required component of the remyelination process. Remyelination of multiple sclerosis lesions is considered to promote recovery from clinical relapses. (Miron et al., Ann. Neurol., 63:61-71, 2008; Coelho et al., J. Pharmacol. Exp. Ther., 323:626-635, 2007; Dev et al., Pharmacology and Therapeutics, 117:77-93, 2008). It also has been shown that the S1P<com:Sub>1< / com:Sub> receptor plays a role in platelet-derived growth factor (PDGF)-induced oligodendrocyte progenitor cell mitogenesis (Jung et al., Glia, 55:1656-1667, 2007). Agonism of the S1P<com:Sub>1< / com:Sub> receptor has also been reported to mediate migration of neural stem cells toward injured areas of the central nervous system (CNS), including in a rat model of spinal cord injury (Kimura et al., Stem Cells, 25:115-124, 2007). Agonism of the S1P<com:Sub>1< / com:Sub> receptor has been implicated in the inhibition of keratinocyte proliferation (Sauer et al., J. Biol. Chem., 279:38471-38479, 2004), consistent with reports that S1P inhibits keratinocyte proliferation (Kim et al., Cell Signal, 16:89-95, 2004). The hyperproliferation of keratinocytes at the entrance to the hair follicle, which can then become blocked, and an associated inflammation are significant pathogenetic factors of acne (Koreck et al., Dermatology, 206:96-105, 2003; Webster, Cutis, 76:4-7, 2005). FTY720 has been reported to have therapeutic efficacy in inhibiting pathologic angiogenesis, such as that as may occur in tumor development. Inhibition of angiogenesis by FTY720 is thought to involve agonism of the S1P<com:Sub>1< / com:Sub> receptor (Oo et al., J. Biol. Chem., 282;9082-9089, 2007; Schmid et al., J. Cell Biochem., 101:259-270, 2007). FTY720 has been reported to have therapeutic efficacy for inhibiting primary and metastatic tumor growth in a mouse model of melanoma (LaMontagne et al., Cancer Res., 66:221-231, 2006). FTY720 has been reported to have therapeutic efficacy in a mouse model for metastatic hepatocellular carcinoma (Lee et al., Clin. Cancer Res., 11:84588466, 2005). It has been reported that oral administration of FTY720 to mice potently blocked VEGF- induced vascular permeability, an important process associated with angiogenesis, inflammation, and pathological conditions such as sepsis, hypoxia, and solid tumor growth (T Sanchez et al., J. Biol. Chem., 278(47), 47281-47290, 2003). FTY720 has been shown to have the rapeutic efficacy in transplant rejection both as a monotherapy and in synergistic combination with a classical immunosuppressant, including cyclosporin A, FK506 and RAD (an mTOR inhibitor). It has been shown that, unlike the classical immunosuppressants cyclosporin A, FK506 and RAD, FTY720 has efficacy for prolonging graft survival without inducing general immunosuppression, and this difference in drug action is believed to be relevant to the synergism observed for the combination (Brinkmann et al., Transplant Proc., 33:530- 531, 2001; Brinkmann et al., Transplantation, 72:764-769, 2001). Agonism of the S1P<com:Sub>1< / com:Sub> receptor has been reported to have therapeutic efficacy for prolonging allograft survival in mouse and rat skin allograft models (Lima et al., Transplant Proc., 36:1015-1017, 2004; Yan et al., Bioorg. & Med. Chem. Lett., 16:3679-3683, 2006). FTY720 has been reported to have therapeutic efficacy for prolonging allograft survival in a rat cardiac allograft model (Suzuki et al., Transpl. Immunol., 4:252-255, 1996). FTY720 has been reported to act synergistically with cyclosporin A to prolong rat skin allograft survival (Yanagawa et al., J. Immunol., 160:5493-5499, 1998), to act synergistically with cyclosporin A and with FK506 to prolong rat cardiac allograft survival, and to act synergistically with cyclosporin A to prolong canine renal allograft survival and monkey renal allograft survival (Chiba et al., Cell Mol. Biol., 3:11-19, 2006). KRP-203, an S1P receptor agonist has been reported to have therapeutic efficacy for prolonging allograft survival in a rat skin allograft model and both as monotherapy and in synergistic combination with cyclosporin A in a rat cardiac allograft model (Shimizu et al., Circulation, 111:222-229, 2005). KRP-203 also has been reported to have therapeutic efficacy in combination with mycophenolate mofetil (MMF; a prodrug for which the active metabolite is mycophenolic acid, an inhibitor of purine biosynthesis) for prolonging allograft survival both in a rat renal allograft model and in a rat cardiac allograft model (Suzuki et al., J. Heart Lung Transplant, 25:302-209, 2006; Fujishiro et al., J. Heart Lung Transplant, 25:825-833, 2006). It has been reported that an agonist of the S1P<com:Sub>1< / com:Sub> receptor, AUY954, in combination with a subtherapeutic dose of RAD001 (Certican / Everolimus, an mTOR inhibitor) can prolong rat cardiac allograft survival (Pan et al., Chemistry & Biology, 13:1227-1234, 2006). In a rat small bowel allograft model, FTY720 has been reported to act synergistically with cyclosporin A to prolong small bowel allograft survival (Sakagawa et al., Transpl. Immunol., 13:161-168, 2004). FTY720 has been reported to have therapeutic efficacy in a mouse islet graft model (Fu et al., Transplantation, 73:1425-1430, 2002; Liu et al., Microsurgery, 27:300-304; 2007) and in a study using human islet cells to evidence no detrimental effects on human islet function (Truong et al., American Journal of Transplantation, 7:2031-2038, 2007). FTY720 has been reported to reduce the nociceptive behavior in the spared nerve injury model for neuropathic pain which does not depend on prostaglandin synthesis (O. Costu et al., Journal of Cellular and Molecular Medicine 12(3), 995-1004, 2008). FTY720 has been reported to impair initiation of murine contact hypersensitivity (CHS). Adoptive transfer of immunized lymph node cells from mice treated with FTY720 during the sensitization phase was virtually incapable of inducing CHS response in recipients (D. Nakashima et al., J. Investigative Dermatology (128(12), 2833-2841, 2008). It has been reported that prophylactic oral administration of FTY720 (1 mg / kg, three times a week), completely prevented the development of experimental autoimmune myasthenia gravis (EAMG) in C57BL / 6 mice (T. Kohono et al., Biological & Pharmaceutical Bulletin, 28(4), 736-739, 2005). S1P<com:Sub>i< / com:Sub> receptor agonists are useful for treating or preventing conditions where suppression of the immune system or agonism of the S1P<com:Sub>1< / com:Sub> receptor is in order, such as diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders, and conditions that have an underlying defect in vascular integrity or that relate to angiogenesis such as may be pathologic. In some embodiments, an S1P<com:Sub>1< / com:Sub> receptor-associated disorder is selected from, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions that have an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis). Such conditions where suppression of the immune system or agonism of the S1P<com:Sub>1< / com:Sub> receptor is in order include diseases and disorders mediated by lymphocytes, conditions that have an underlying defect in vascular integrity, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), acute or chronic rejection of cells, an autoimmune disease of the liver including biliary cirrhosis, primary biliary cirrhosis, autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cholangitis, tissue or solid organ grafts, arthritis including psoriatic arthritis and rheumatoid arthritis, diabetes including type I diabetes and the disorders associated therewith, myasthenia gravis, demyelinating disease including multiple sclerosis, ischemia-reperfusion injury including renal and cardiac ischemia-reperfusion injury, inflammatory skin disease including psoriasis, atopic dermatitis and acne, hyperproliferative skin disease including acne, inflammatory bowel disease including Crohn's disease and ulcerative colitis, systemic lupus erythematosus, asthma, uveitis, myocarditis, allergy, atherosclerosis, brain inflammation including Alzheimer's disease and brain inflammatory reaction following traumatic brain injury, central nervous system disease including spinal cord injury or cerebral infarction, pathologic angiogenesis including as may occur in primary and metastatic tumor growth, rheumatoid arthritis, diabetic retinopathy and atherosclerosis, cancer, chronic pulmonary disease, acute lung injury, acute respiratory disease syndrome, sepsis, and the like. In addition, S1P<com:Sub>1< / com:Sub> receptor agonists are useful for treating microbial infections, and viral infections or diseases. One aspect of the present invention relates to methods for treating an S1P<com:Sub>1< / com:Sub> receptor-associated disorder in an individual comprising administering to the individual in need thereof a therapeutically effective amount of a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydr...
Claims
1. A method for preparing a crystalline free-plate habit of L-arginine salt of ( R ) (R) -2- ( 7 (7 - ( 4 (4 - cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, said method comprising the steps of: a) forming a first mixture comprising L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, a water- miscible anti-solvent, and H 2 O; b) heating the first mixture to a first heating temperature to form a second mixture; wherein said first heating temperature is about 79°C to about 85°C; c) adding a first additional amount of said water-miscible anti-solvent to said second mixture while maintaining said first heating temperature to form a suspension; d) cooling the suspension to a first cooling temperature and thereafter heating to a second heating temperature; wherein said first cooling temperature is about 18°C to about 22°C, and said second heating temperature is about 69°C to about 73°C; e) cycling Step d) optionally one or more times, wherein the first cooling temperature at each cycle may be the same or different and the second heating temperature at each cycle may be the same or different; and f) cooling said suspension to a final cooling temperature to form said crystalline free- plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid; wherein said final cooling temperature is about 18°C to about 22°C.
2. The method according to claim 1, wherein said water-miscible anti-solvent comprises a solvent selected from the group consisting of: acetonitrile, acetone, tetrahydrofuran, and C 2 -C 4 alkanol.
3. The method according to claim 1 or 2, wherein forming said first mixture in Step a) comprises the step of adding L-arginine and H 2 O, either together or separately in any order, to a salt-forming mixture comprising (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol- 3-yl)acetic acid and said water-miscible anti-solvent to form said first mixture.
4. The method according to claim 3, wherein said adding L-arginine and H 2 O is conducted under an inert atmosphere comprising nitrogen.
5. The method according to claim 3 or 4, wherein the molar ratio between ( R ) (R) -2- ( 7 (7 - ( 4 (4 -cyclopentyl- 3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L- arginine is about 1.0:0.93 to about 1.0:1.01.
6. The method according to any one of claims 3 to 5, wherein the weight ratio of L-arginine and H 2 O is about 1.0:1.2 to about 1.0:1.5.
7. The method according to any one of claims 3 to 6, wherein said salt-forming mixture prior to said adding L-arginine is at a temperature of about 18°C to about 30°C.
8. The method according to any one of claims 3 to 7, wherein said salt-forming mixture during said adding L-arginine is at a temperature of about 18°C to about 30°C.
9. The method according to any one of claims 3 to 8, wherein said water-miscible anti-solvent comprises 2-propanol and wherein prior to adding said L-arginine and H 2 O, said salt-forming mixture comprises (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3- yl)acetic acid and 2-propanol in a weight ratio of about 1.0:6.0 to about 1.0:8.0.
10. The method according to any one of claims 3 to 9, wherein said water-miscible anti-solvent comprises 2-propanol and wherein said salt-forming mixture comprises ( R ) (R) -2- ( 7 (7 - ( 4 (4 -cyclopentyl- 3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid, 2- propanol, and water in a weight ratio of about 1.0:6.0:0.25 to about 1.0:8.0:0.7.
11. The method according to any one of claims 1 to 8, wherein said water-miscible anti-solvent comprises 2-propanol.
12. The method according to claim 11, wherein the weight ratio of L-arginine salt of ( R ) (R) -2- ( 7 − ( 4 − (7-(4- cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to said first additional amount of 2-propanol is about 1.00:5.95 to about 1.00:6.25.
13. The method according to any one of claims 1 to 12, wherein said second mixture is substantially a homogeneous solution.
14. The method according to any one of claims 1 to 13, wherein said first additional amount of said water-miscible anti-solvent is added during a first time point and a second time point.
15. The method according to claim 14, wherein about 8% to about 12% of said first additional amount of said water-miscible anti-solvent is added at said first time point.
16. The method according to 14 or 15, wherein said first additional amount of said water-miscible anti-solvent is added at said first time point to form a cloudy mixture.
17. The method according to any one of claims 14 to 16, wherein prior to said second time point, a seed crystal of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid is optionally added.
18. The method according to any one of claims 14 to 16, wherein said first additional amount of said water-miscible anti-solvent is added at said second time point at a rate to complete the addition in about 1.00 hour or greater.
19. The method according to any one of claims 1 to 18, wherein cooling said suspension to said first cooling temperature in Step d) is conducted at a rate of about 9°C / hour to about 11°C / hour.
20. The method according to any one of claims 1 to 19, wherein said cycling in Step e) comprises said cycling Step d) two times.
21. The method according to claim 20, wherein said cycling Step e) two times comprises cooling the suspension to a first cycling cooling temperature, heating the suspension to a first cycling heating temperature, cooling the suspension to a second cycling cooling temperature, and heating the suspension to a second cycling heating temperature.
22. The method according to claim 21, wherein said first cycling cooling temperature is about 16°C to about 26°C, said first cycling heating temperature is about 55°C to about 65°C, said second cycling cooling temperature is about 26°C to about 36°C, and said second cycling heating temperature is about 45°C to about 55°C.
23. The method according to any one of claims 1 to 19, wherein said cycling in Step e) comprises said cycling Step d) three times.
24. The method according to claim 23, wherein said cycling Step e) three times comprises: cooling the suspension to a first cycling cooling temperature, heating the suspension to a first cycling heating temperature, cooling the suspension to a second cycling cooling temperature, heating the suspension to a second cycling heating temperature, cooling the suspension to a third cycling cooling temperature, and heating the suspension to a third cycling heating temperature.
25. The method according to claim 24, wherein said first cycling cooling temperature is about 16°C to about 26°C, said first cycling heating temperature is about 66°C to about 76°C, said second cycling cooling temperature is about 16°C to about 26°C, said second cycling heating temperature is about 55°C to about 65°C, said third cycling cooling temperature is about 26°C to about 36°C, and said third cycling heating temperature is about 45°C to about 55°C.
26. A method according to claim 1, for preparing a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)acetic acid, said method comprising the steps of: a) hydrolyzing a compound of Formula (IIa): [Image disponible dans le document PDF, Image available in the PDF document] wherein R 3 R^3 is C 1 C_1 - C 6 C_6 alkyl; in the presence of a hydrolyzing mixture comprising a lipase and a hydrolyzing-step solvent to form ( R ) (R) -2- ( 7 (7 - ( 4 (4 -cyclopentyl-3- ( t r i f l u o r o m e t h y l ) (trifluoromethyl) benzyloxy)- 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; b) forming a first mixture comprising L-arginine salt of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid, a water- miscible anti-solvent, and H 2 O; c) heating the first mixture to a first heating temperature to form a second mixture; wherein said first heating temperature is about 79°C to about 85°C; d) adding a first additional amount of said water-miscible anti-solvent to said second mixture while maintaining said first heating temperature to form a suspension; e) cooling said suspension to a first cooling temperature and thereafter heating to a second heating temperature; wherein said first cooling temperature is about 18°C to about 22°C, and said second heating temperature is about 69°C to about 73°C; f) cycling Step e) optionally one or more times, wherein said first cooling temperature at each cycle may be the same or different and said second heating temperature at each cycle may be the same or different; and g) cooling said suspension to a final cooling temperature to form said crystalline free- plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid; wherein said final cooling temperature is about 18°C to about 22°C.
27. The method according to claim 26, wherein said hydrolyzing-step solvent comprises acetonitrile.
28. The method according to claim 26, wherein: said compound of Formula (IIa) is: [Image disponible dans le document PDF, Image available in the PDF document] said lipase is immobilized Candida Antarctica lipase B; and said hydrolyzing-step solvent comprises acetonitrile.
29. The method according to any one of claims 26 to 28, wherein said hydrolyzing is conducted in the presence of a phosphate buffer at a pH of about 6.9 to about 8.1, wherein said phosphate buffer is a potassium phosphate buffer.
30. The method according to any one of claims 26 to 29, wherein said hydrolyzing is conducted at a temperature of about 35°C to about 45°C.
31. The method according to any one of claims 26 to 30, wherein after said hydrolyzing, said ( R ) (R) -2- (7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)acetic acid is not isolated.
32. The method according to claim 31, wherein after said hydrolyzing, said ( R ) (R) -2- ( 7 − ( 4 − (7-(4- cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid is present in an amount of at least 40% as determined by HPLC.
33. The method according to any one of claims 26 to 32, wherein said water-miscible anti-solvent comprises a solvent selected from the group consisting of: acetonitrile, acetone, tetrahydrofuran, and C 2 C_2 - C 4 C_4 alkanol.
34. The method according to any one of claims 26 to 33, wherein forming said first mixture in Step b) comprises the step of adding L-arginine and H 2 O, either together or separately in any order, to a salt-forming mixture comprising ( R ) (R) -2- ( 7 (7 - ( 4 (4 -cyclopentyl-3- ( t r i f l u o r o m e t h y l ) (trifluoromethyl) benzyloxy)- 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and said water-miscible anti-solvent to form said first mixture.
35. The method according to claim 34, wherein said adding L-arginine and H 2 O is conducted under an inert atmosphere comprising nitrogen.
36. The method according to claim 34 or 35, wherein the molar ratio between ( R ) (R) -2- ( 7 (7 - ( 4 (4 - cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and L-arginine is about 1.0:0.93 to about 1.0:1.01.
37. The method according to any one of claims 34 to 36, wherein the weight ratio of L-arginine and H 2 O H_2O is about 1.0:1.2 to about 1.0:1.5.
38. The method according to any one of claims 34 to 37, wherein said salt-forming mixture prior to said adding L-arginine is at a temperature of about 18°C to about 30°C.
39. The method according to any one of claims 34 to 38, wherein said salt-forming mixture during said adding L-arginine is at a temperature of about 18°C to about 30°C.
40. The method according to any one of claims 34 to 39, wherein said water-miscible anti-solvent comprises 2-propanol and wherein prior to adding said L-arginine and H 2 O, said salt-forming mixture comprises (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro- cyclopenta[b]indol-3-yl)acetic acid and 2-propanol in a weight ratio of about 1.0:6.0 to about 1.0:8.0.
41. The method according to any one of claims 34 to 40, wherein said water-miscible anti-solvent comprises 2-propanol and wherein said salt-forming mixture comprises ( R ) (R) -2- ( 7 (7 - ( 4 (4 -cyclopentyl- 3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)acetic acid, 2- propanol, and water in a weight ratio of about 1.0:6.0:0.25 to about 1.0:8.0:0.7.
42. The method according to any one of claims 26 to 39, wherein said water-miscible anti-solvent comprises 2-propanol.
43. The method according to claim 42, wherein the weight ratio of L-arginine salt of ( R ) (R) -2- ( 7 − ( 4 − (7-(4- cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid to said first additional amount of 2-propanol is about 1.00:5.95 to about 1.00:6.25.
44. The method according to any one of claims 26 to 43, wherein said second mixture is substantially a homogeneous solution.
45. The method according to any one of claims 26 to 44, wherein said first additional amount of said water-miscible anti-solvent is added during a first time point and a second time point.
46. The method according to claim 45, wherein about 8% to about 12% of said first additional amount of said water-miscible anti-solvent is added at said first time point.
47. The method according to claim 45 or 46, wherein said first additional amount of said water- miscible anti-solvent is added at said first time point to form a cloudy mixture.
48. The method according to any one of claims 45 to 47, wherein prior to said second time point, a seed crystal of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid is optionally added.
49. The method according to any one of claims 45 to 47, wherein said first additional amount of said water-miscible anti-solvent is added at said second time point at a rate to complete the addition in about 1.00 hour or greater.
50. The method according to any one of claims 26 to 49, wherein cooling said suspension to said first cooling temperature in Step e) is conducted at a rate of about 9°C / hour to about 11°C / hour.
51. The method according to any one of claims 26 to 50, wherein said cycling in Step f) comprises said cycling Step e) two times.
52. The method according to claim 51, wherein said cycling Step f) two times comprises cooling the suspension to a first cycling cooling temperature, heating the suspension to a first cycling heating temperature, cooling the suspension to a second cycling cooling temperature, and heating the suspension to a second cycling heating temperature.
53. The method according to claim 52, wherein said first cycling cooling temperature is about 16°C to about 26°C, said first cycling heating temperature is about 55°C to about 65°C, said second cycling cooling temperature is about 26°C to about 36°C, and said second cycling heating temperature is about 45°C to about 55°C.
54. The method according to any one of claims 26 to 50, wherein said cycling in Step f) comprises said cycling Step e) three times.
55. The method according to claim 54, wherein said cycling Step f) three times comprises: cooling the suspension to a first cycling cooling temperature, heating the suspension to a first cycling heating temperature, cooling the suspension to a second cycling cooling temperature, heating the suspension to a second cycling heating temperature, cooling the suspension to a third cycling cooling temperature, and heating the suspension to a third cycling heating temperature.
56. The method according to claim 55, wherein said first cycling cooling temperature is about 16°C to about 26°C, said first cycling heating temperature is about 66°C to about 76°C, said second cycling cooling temperature is about 16°C to about 26°C, said second cycling heating temperature is about 55°C to about 65°C, said third cycling cooling temperature is about 26°C to about 36°C, and said third cycling heating temperature is about 45°C to about 55°C.
57. A crystalline free-plate habit of L-arginine salt of ( R ) (R) -2- ( 7 (7 - ( 4 (4 -cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; wherein said crystalline free-plate habit has a BET specific surface area of about 0.1 m 2 / g 0.1 \text{ m}^2 / \text{g} to about 5.0 m 2 / g 5.0 \text{ m}^2 / \text{g} .
58. A crystalline free-plate habit of L-arginine salt of ( R ) (R) -2- ( 7 (7 - ( 4 (4 -cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; wherein the crystalline free-plate habit is characterised by hexagonal-like plates with two opposite sides of the plate being longer than the other sides; wherein the crystalline free-plate habit comprises complete plates, substantially complete plates, fragments / broken pieces of plates, and mixtures thereof that are free or substantially free of radial clusters or spherulites; and wherein radial clusters and spherulites are a crystal habit consisting of plates or flakes that are clustered in a radial manner around a nucleation site.
59. A crystalline free-plate habit of L-arginine salt of ( R ) (R) -2- ( 7 (7 - ( 4 (4 -cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; wherein the crystalline free-plate habit is characterised by hexagonal-like plates with two opposite sides of the plate being longer than the other sides as measured by microscopy; wherein the crystalline free-plate habit is free of radial clusters or spherulites; and wherein radial clusters and spherulites are a crystal habit consisting of plates or flakes that are clustered in a radial manner around a nucleation site.
60. The crystalline free-plate habit according to claim 58 or 59, having a BET specific surface area of about 0.1 m 2 / g 0.1 \text{ m}^2 / \text{g} to about 5.0 m 2 / g 5.0 \text{ m}^2 / \text{g} .
61. The crystalline free-plate habit according to any one of claims 57 to 60, having a BET specific surface area of about 0.6 m 2 / g 0.6 \text{ m}^2 / \text{g} to about 4.0 m 2 / g 4.0 \text{ m}^2 / \text{g} .
62. The crystalline free-plate habit according to any one of claims 57 to 60, having a BET specific surface area of about 0.6 m 2 / g 0.6 \text{ m}^2 / \text{g} to about 1.6 m 2 / g 1.6 \text{ m}^2 / \text{g} .
63. The crystalline free-plate habit according to any one of claims 57 to 62, having a powder X-ray diffraction pattern comprising peaks, in terms of 2 θ 2\theta , at 8.2 ∘ ± 0.2 ∘ 8.2^{\circ} \pm 0.2^{\circ} , 16.4 ∘ ± 0.2 ∘ 16.4^{\circ} \pm 0.2^{\circ} , and 20.5 ∘ ± 0.2 ∘ 20.5^{\circ} \pm 0.2^{\circ} .
64. The crystalline free-plate habit according to any one of claims 57 to 62, having a powder X-ray diffraction pattern comprising peaks, in terms of 2 θ 2\theta , at 8.2 ∘ ± 0.2 ∘ 8.2^{\circ} \pm 0.2^{\circ} , 16.4 ∘ ± 0.2 ∘ 16.4^{\circ} \pm 0.2^{\circ} , 20.5 ∘ ± 0.2 ∘ 20.5^{\circ} \pm 0.2^{\circ} , and 24.6 ∘ ± 0.2 ∘ 24.6^{\circ} \pm 0.2^{\circ} .
65. The crystalline free-plate habit according to any one of claims 57 to 62, having a powder X-ray diffraction pattern comprising peaks, in terms of 2 θ 2\theta , at 8.2 ∘ ± 0.2 ∘ 8.2^{\circ} \pm 0.2^{\circ} , 16.4 ∘ ± 0.2 ∘ 16.4^{\circ} \pm 0.2^{\circ} , 20.5 ∘ ± 0.2 ∘ 20.5^{\circ} \pm 0.2^{\circ} , 24.6 ∘ ± 0.2 ∘ 24.6^{\circ} \pm 0.2^{\circ} , 28.8 ∘ ± 0.2 ∘ 28.8^{\circ} \pm 0.2^{\circ} , and 37.3 ∘ ± 0.2 ∘ 37.3^{\circ} \pm 0.2^{\circ} .
66. The crystalline free-plate habit according to any one of claims 57 to 65, having a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of67. The crystalline free-plate habit according to any one of claims 57 to 65, having a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of68. The crystalline free-plate habit according to any one of claims 57 to 65, having a differential scanning calorimetry trace conducted at a scan rate of 10°C / minute comprising an endotherm substantially as depicted in any one of Figures 6 to 10 and Figures 22 to 25.
69. The crystalline free-plate habit according to any one of claims 57 to 68, having a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.3% weight or less at 90% RH.
70. The crystalline free-plate habit according to any one of claims 57 to 62, having: 1) a powder X-ray diffraction pattern comprising peaks, in terms of 2 θ 2\theta , at 8.2 ∘ ± 0.2 ∘ 8.2^{\circ} \pm 0.2^{\circ} , 16.4 ∘ ± 0.2 ∘ 16.4^{\circ} \pm 0.2^{\circ} , and 20.5 ∘ ± 0.2 ∘ 20.5^{\circ} \pm 0.2^{\circ} ; 2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.0°C to 208.5°C at a scan rate of 10°C / minute; and / or 3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.3% weight or less at 90% RH.
71. The crystalline free-plate habit according to any one of claims 57 to 60, having: 1) a powder X-ray diffraction pattern comprising peaks, in terms of 2 θ 2\theta , at 8.2 ∘ ± 0.2 ∘ 8.2^{\circ} \pm 0.2^{\circ} , 16.4 ∘ ± 0.2 ∘ 16.4^{\circ} \pm 0.2^{\circ} , 20.5 ∘ ± 0.2 ∘ 20.5^{\circ} \pm 0.2^{\circ} , and 24.6 ∘ ± 0.2 ∘ 24.6^{\circ} \pm 0.2^{\circ} ; 2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°C to 208.5°C at a scan rate of 10°C / minute; 3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.3% weight or less at 90% RH; and / or 4) a BET specific surface area of about 0.6 m 2 / g 0.6 \text{ m}^2 / \text{g} to about 4.0 m 2 / g 4.0 \text{ m}^2 / \text{g} .
72. The crystalline free-plate habit according to any one of claims 57 to 60, having: 1) a powder X-ray diffraction pattern comprising peaks, in terms of 2 θ 2\theta , at 8.2 ∘ ± 0.2 ∘ 8.2^{\circ} \pm 0.2^{\circ} , 16.4 ∘ ± 0.2 ∘ 16.4^{\circ} \pm 0.2^{\circ} , 20.5 ∘ ± 0.2 ∘ 20.5^{\circ} \pm 0.2^{\circ} , 24.6 ∘ ± 0.2 ∘ 24.6^{\circ} \pm 0.2^{\circ} , 28.8 ∘ ± 0.2 ∘ 28.8^{\circ} \pm 0.2^{\circ} , and 37.3 ∘ ± 0.2 ∘ 37.3^{\circ} \pm 0.2^{\circ} ; 2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°C to 208.1°C at a scan rate of 10°C / minute; 3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.2% weight or less at 90% RH; and / or 4) a BET specific surface area of about 0.6 m 2 / g 0.6 \text{ m}^2 / \text{g} to about 4.0 m 2 / g 4.0 \text{ m}^2 / \text{g} .
73. L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid in the form of a crystalline free-plate habit substantially free of radial clusters or spherulites.
74. L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid in the form of a crystalline free-plate habit containing a total amount of compound A and compound B that is less than 0.9% after storage for six months at 40°C / 75% RH, wherein compound A and compound B have the following formulae: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document]75. L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid in the form of a crystalline free-plate habit having a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.3% weight or less at 90% RH.
76. L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl)acetic acid in the form of a crystalline free-plate habit having a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.0°C to 208.5°C at a scan rate of 10°C / minute.
77. The L-arginine salt according to any one of claims 73 to 76, wherein the crystalline free-plate habit has a BET specific surface area of about 0.1 m 2 / g 0.1 \text{ m}^2 / \text{g} to about 5.0 m 2 / g 5.0 \text{ m}^2 / \text{g} .
78. The L-arginine salt according to any one of claims 73 to 77, wherein the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2 θ 2\theta , at 8.2 ∘ ± 0.2 ∘ 8.2^{\circ} \pm 0.2^{\circ} , 16.4 ∘ ± 0.2 ∘ 16.4^{\circ} \pm 0.2^{\circ} , and 20.5 ∘ ± 0.2 ∘ 20.5^{\circ} \pm 0.2^{\circ} .
79. The L-arginine salt according to any one of claims 73 to 77, wherein the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2 θ 2\theta , at 8.2 ∘ ± 0.2 ∘ 8.2^{\circ} \pm 0.2^{\circ} , 16.4 ∘ ± 16.4^{\circ} \pm 0.2 ∘ 0.2^{\circ} , 20.5 ∘ ± 0.2 ∘ 20.5^{\circ} \pm 0.2^{\circ} , and 24.6 ∘ ± 0.2 ∘ 24.6^{\circ} \pm 0.2^{\circ} .
80. The L-arginine salt according to any one of claims 73 to 77, wherein the crystalline free-plate habit has a powder X-ray diffraction pattern comprising peaks, in terms of 2 θ 2\theta , at 8.2 ∘ ± 0.2 ∘ 8.2^{\circ} \pm 0.2^{\circ} , 16.4 ∘ ± 0.2 ∘ 16.4^{\circ} \pm 0.2^{\circ} , 20.5 ∘ ± 0.2 ∘ 20.5^{\circ} \pm 0.2^{\circ} , 24.6 ∘ ± 0.2 ∘ 24.6^{\circ} \pm 0.2^{\circ} , 28.8 ∘ ± 0.2 ∘ 28.8^{\circ} \pm 0.2^{\circ} , and 37.3 ∘ ± 0.2 ∘ 37.3^{\circ} \pm 0.2^{\circ} .
81. The L-arginine salt according to any one of claims 73 to 80, wherein the crystalline free-plate habit has a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°C to 208.1°C at a scan rate of 10°C / minute.
82. The L-arginine salt according to any one of claims 73 to 80, wherein the crystalline free-plate habit has a differential scanning calorimetry trace conducted at a scan rate of 10°C / minute comprising an endotherm substantially as depicted in any one of Figures 6 to 10 and Figures 22 to 25.
83. The L-arginine salt according to claim 73, 74 or 76, wherein the crystalline free plate habit has: 1) a powder X-ray diffraction pattern comprising peaks, in terms of 2 θ 2\theta , at 8.2 ∘ ± 0.2 ∘ 8.2^{\circ} \pm 0.2^{\circ} , 16.4 ∘ ± 0.2 ∘ 16.4^{\circ} \pm 0.2^{\circ} , 20.5 ∘ ± 0.2 ∘ 20.5^{\circ} \pm 0.2^{\circ} , and 24.6 ∘ ± 0.2 ∘ 24.6^{\circ} \pm 0.2^{\circ} ; 2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°C to 208.5°C at a scan rate of 10°C / minute; 3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.3% weight or less at 90% RH; and / or 4) a BET specific surface area of about 0.6 m 2 / g 0.6 \text{ m}^2 / \text{g} to about 4.0 m 2 / g 4.0 \text{ m}^2 / \text{g} .
84. The L-arginine salt according to claim 73, 74 or 76, wherein the crystalline free plate habit has: 1) a powder X-ray diffraction pattern comprising peaks, in terms of 2 θ 2\theta , at 8.2 ∘ ± 0.2 ∘ 8.2^{\circ} \pm 0.2^{\circ} , 16.4 ∘ ± 0.2 ∘ 16.4^{\circ} \pm 0.2^{\circ} , 20.5 ∘ ± 0.2 ∘ 20.5^{\circ} \pm 0.2^{\circ} , 24.6 ∘ ± 0.2 ∘ 24.6^{\circ} \pm 0.2^{\circ} , 28.8 ∘ ± 0.2 ∘ 28.8^{\circ} \pm 0.2^{\circ} , and 37.3 ∘ ± 0.2 ∘ 37.3^{\circ} \pm 0.2^{\circ} ; 2) a differential scanning calorimetry trace comprising an endotherm with an extrapolated onset temperature of 205.5°C to 208.1°C at a scan rate of 10°C / minute; 3) a dynamic moisture sorption (DMS) profile with an adsorption phase from 30% RH to 90% RH wherein said crystalline free-plate habit gains about 0.2% weight or less at 90% RH; and / or 4) a BET specific surface area of about 0.6 m 2 / g 0.6 \text{ m}^2 / \text{g} to about 4.0 m 2 / g 4.0 \text{ m}^2 / \text{g} .
85. A composition comprising a crystalline free-plate habit of L-arginine salt of ( R ) (R) -2- ( 7 (7 - ( 4 (4 - cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid according to any one of claims 57 to 72 or the L-arginine salt according to any one of claims 73 to 84 and a carrier.
86. A pharmaceutical composition comprising a crystalline free-plate habit of L-arginine salt of ( R ) (R) - 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3- yl)acetic acid according to any one of claims 57 to 72 or the L-arginine salt according to any one of claims 73 to 84 and a pharmaceutical excipient.
87. A pharmaceutical composition prepared by a method comprising mixing a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4- tetrahydrocyclo-penta[b]indol-3-yl)acetic acid according to any one of claims 57 to 72 or the L- arginine salt according to any one of claims 73 to 84 with a pharmaceutically acceptable carrier.
88. The pharmaceutical composition according to claim 86 or 87, wherein said pharmaceutical composition is suitable for oral administration.
89. The pharmaceutical composition of any one of claims 86 to 88, wherein the pharmaceutical composition is in the form of a tablet.
90. Use of a therapeutically effective amount of a crystalline free-plate habit of L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3- yl)acetic acid according to any one of claims 57 to 72, the L-arginine salt according to any one of claims 73 to 84, a composition according to claim 85, or a pharmaceutical composition according to any one of claims 86 to 89 for treatment of an S1P 1 receptor-associated disorder in an individual in need thereof.
91. The use according to claim 90, wherein the S1P 1 receptor-associated disorder is selected from the group consisting of a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, primary biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, atopic dermatitis and acne.
92. The use according to claim 90, wherein the S1P 1 receptor-associated disorder is primary biliary cirrhosis.
93. The use according to claim 90, wherein the S1P 1 receptor-associated disorder is psoriasis.
94. The use according to claim 90, wherein the S1P 1 receptor-associated disorder is psoriatic arthritis.
95. The use according to claim 90, wherein the S1P 1 receptor-associated disorder is rheumatoid arthritis.
96. The use according to claim 90, wherein the S1P 1 receptor-associated disorder is Crohn's disease.
97. The use according to claim 90, wherein the S1P 1 receptor-associated disorder is transplant rejection.
98. The use according to claim 90, wherein the S1P 1 receptor-associated disorder is multiple sclerosis.
99. The use according to claim 90, wherein the S1P 1 receptor-associated disorder is systemic lupus erythematosus.
100. The use according to claim 90, wherein the S1P 1 receptor-associated disorder is inflammatory bowel disease.
101. The use according to claim 90, wherein the S1P 1 receptor-associated disorder is ulcerative colitis.
102. The use according to claim 90, wherein the S1P 1 receptor-associated disorder is type I diabetes.
103. The use according to claim 90, wherein the S1P 1 receptor-associated disorder is atopic dermatitis.
104. The use according to claim 90, wherein the S1P 1 receptor-associated disorder is inflammatory skin disease.
105. The use according to claim 90, wherein the S1P 1 receptor-associated disorder is acne.
106. The use according to claim 90, wherein the S1P 1 receptor-associated disorder is a disease or disorder mediated by lymphocytes.
107. The use according to claim 90, wherein the S1P 1 receptor-associated disorder is an autoimmune disease or disorder.
108. The use according to claim 90, wherein the S1P 1 receptor-associated disorder is an inflammatory disease or disorder.
109. Use of a crystalline free-plate habit of L-arginine salt of ( R ) (R) -2- ( 7 (7 - ( 4 (4 -cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid according to any one of claims 57 to 72, the L-arginine salt according to any one of claims 73 to 84, a composition according to claim 85, or a pharmaceutical composition according to any one of claims 86 to 89 in the manufacture of a medicament for the treatment of an S1P 1 receptor- associated disorder.
110. The use according to claim 109, wherein the S1P 1 receptor-associated disorder is selected from the group consisting of a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, primary biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, atopic dermatitis and acne.
111. The use according to claim 109, wherein the S1P 1 receptor-associated disorder is primary biliary cirrhosis.
112. The use according to claim 109, wherein the S1P 1 receptor-associated disorder is psoriasis.
113. The use according to claim 109, wherein the S1P 1 receptor-associated disorder is psoriatic arthritis.
114. The use according to claim 109, wherein the S1P 1 receptor-associated disorder is rheumatoid arthritis.
115. The use according to claim 109, wherein the S1P 1 receptor-associated disorder is Crohn's disease.
116. The use according to claim 109, wherein the S1P 1 receptor-associated disorder is transplant rejection.
117. The use according to claim 109, wherein the S1P 1 receptor-associated disorder is multiple sclerosis.
118. The use according to claim 109, wherein the S1P 1 receptor-associated disorder is systemic lupus erythematosus.
119. The use according to claim 109, wherein the S1P 1 receptor-associated disorder is inflammatory bowel disease.
120. The use according to claim 109, wherein the S1P 1 receptor-associated disorder is ulcerative colitis.
121. The use according to claim 109, wherein the S1P 1 receptor-associated disorder is type I diabetes.
122. The use according to claim 109, wherein the S1P 1 receptor-associated disorder is atopic dermatitis.
123. The use according to claim 109, wherein the S1P 1 receptor-associated disorder is inflammatory skin disease.
124. The use according to claim 109, wherein the S1P 1 receptor-associated disorder is acne.
125. The use according to claim 109, wherein the S1P 1 receptor-associated disorder is a disease or disorder mediated by lymphocytes.
126. The use according to claim 109, wherein the S1P 1 receptor-associated disorder is an autoimmune disease or disorder.
127. The use according to claim 109, wherein the S1P 1 receptor-associated disorder is an inflammatory disease or disorder.
128. Use of a composition comprising a crystalline free-plate habit of L-arginine salt of ( R ) (R) -2- ( 7 − ( 4 − (7-(4- cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid according to any one of claims 57 to 72 or L-arginine salt according to any one of claims 73 to 84 and an excipient in the manufacture of a medicament for administration in the treatment of an S1P 1 receptor-associated disorder.
129. The use according to claim 128, wherein the S1P 1 receptor-associated disorder is selected from the group consisting of a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, primary biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, atopic dermatitis and acne.
130. The use according to claim 128, wherein the S1P 1 receptor-associated disorder is primary biliary cirrhosis.
131. The use according to claim 128, wherein the S1P 1 receptor-associated disorder is psoriasis.
132. The use according to claim 128, wherein the S1P 1 receptor-associated disorder is psoriatic arthritis.
133. The use according to claim 128, wherein the S1P 1 receptor-associated disorder is rheumatoid arthritis.
134. The use according to claim 128, wherein the S1P 1 receptor-associated disorder is Crohn's disease.
135. The use according to claim 128, wherein the S1P 1 receptor-associated disorder is transplant rejection.
136. The use according to claim 128, wherein the S1P 1 receptor-associated disorder is multiple sclerosis.
137. The use according to claim 128, wherein the S1P 1 receptor-associated disorder is systemic lupus erythematosus.
138. The use according to claim 128, wherein the S1P 1 receptor-associated disorder is inflammatory bowel disease.
139. The use according to claim 128, wherein the S1P 1 receptor-associated disorder is ulcerative colitis.
140. The use according to claim 128, wherein the S1P 1 receptor-associated disorder is type I diabetes.
141. The use according to claim 128, wherein the S1P 1 receptor-associated disorder is atopic dermatitis.
142. The use according to claim 128, wherein the S1P 1 receptor-associated disorder is inflammatory skin disease.
143. The use according to claim 128, wherein the S1P 1 receptor-associated disorder is acne.
144. The use according to claim 128, wherein the S1P 1 receptor-associated disorder is a disease or disorder mediated by lymphocytes.
145. The use according to claim 128, wherein the S1P 1 receptor-associated disorder is an autoimmune disease or disorder.
146. The use according to claim 128, wherein the S1P 1 receptor-associated disorder is an inflammatory disease or disorder.
147. The use according to any one of claims 128 to 146, wherein the administration is oral administration.
148. The use according to any one of claims 128 to 147, wherein the medicament is in the form of a tablet.
149. A crystalline free-plate habit of L-arginine salt of ( R ) (R) -2- ( 7 (7 - ( 4 (4 -cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid according to any one of claims 57 to 72 or L-arginine salt according to any one of claims 73 to 84 for use in the treatment of the human or animal body by therapy.
150. A crystalline free-plate habit of L-arginine salt of ( R ) (R) -2- ( 7 (7 - ( 4 (4 -cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid according to any one of claims 57 to 72, the L-arginine salt according to any one of claims 73 to 84, a composition according to claim 85, or a pharmaceutical composition according to any one of claims 86 to 89 for use in the treatment of an S1P 1 receptor-associated disorder.
151. The crystalline free-plate habit, L-arginine salt, composition or pharmaceutical composition for use according to claim 150, wherein the S1P1 receptor-associated disorder is selected from the group consisting of a disease or disorder mediated by lymphocytes, an autoimmune disease or disorder, an inflammatory disease or disorder, primary biliary cirrhosis, cancer, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, type I diabetes, atopic dermatitis and acne.
152. The crystalline free-plate habit, L-arginine salt, composition or pharmaceutical composition for use according to claim 150, wherein the S1P 1 receptor-associated disorder is primary biliary cirrhosis.
153. The crystalline free-plate habit, L-arginine salt, composition or pharmaceutical composition for use according to claim 150, wherein the S1P 1 receptor-associated disorder is psoriasis.
154. The crystalline free-plate habit, L-arginine salt, composition or pharmaceutical composition for use according to claim 150, wherein the S1P 1 receptor-associated disorder is psoriatic arthritis.
155. The crystalline free-plate habit, L-arginine salt, composition or pharmaceutical composition for use according to claim 150, wherein the S1P 1 receptor-associated disorder is rheumatoid arthritis.
156. The crystalline free-plate habit, L-arginine salt, composition or pharmaceutical composition for use according to claim 150, wherein the S1P 1 receptor-associated disorder is Crohn's disease.
157. The crystalline free-plate habit, L-arginine salt, composition or pharmaceutical composition for use according to claim 150, wherein the S1P 1 receptor-associated disorder is transplant rejection.
158. The crystalline free-plate habit, L-arginine salt, composition or pharmaceutical composition for use according to claim 150, wherein the S1P 1 receptor-associated disorder is multiple sclerosis.
159. The crystalline free-plate habit, L-arginine salt, composition or pharmaceutical composition for use according to claim 150, wherein the S1P 1 receptor-associated disorder is systemic lupus erythematosus.
160. The crystalline free-plate habit, L-arginine salt, composition or pharmaceutical composition for use according to claim 150, wherein the S1P 1 receptor-associated disorder is inflammatory bowel disease.
161. The crystalline free-plate habit, L-arginine salt, composition or pharmaceutical composition for use according to claim 150, wherein the S1P 1 receptor-associated disorder is ulcerative colitis.
162. The crystalline free-plate habit, L-arginine salt, composition or pharmaceutical composition for use according to claim 150, wherein the S1P 1 receptor-associated disorder is type I diabetes.
163. The crystalline free-plate habit, L-arginine salt, composition or pharmaceutical composition for use according to claim 150, wherein the S1P 1 receptor-associated disorder is atopic dermatitis.
164. The crystalline free-plate habit, L-arginine salt, composition or pharmaceutical composition for use according to claim 150, wherein the S1P 1 receptor-associated disorder is inflammatory skin disease.
165. The crystalline free-plate habit, L-arginine salt, composition or pharmaceutical composition for use according to claim 150, wherein the S1P 1 receptor-associated disorder is acne.
166. The crystalline free-plate habit, L-arginine salt, composition or pharmaceutical composition for use according to claim 150, wherein the S1P 1 receptor-associated disorder is a disease or disorder mediated by lymphocytes.
167. The crystalline free-plate habit, L-arginine salt, composition or pharmaceutical composition for use according to claim 150, wherein the S1P 1 receptor-associated disorder is an autoimmune disease or disorder.
168. The crystalline free-plate habit, L-arginine salt, composition or pharmaceutical composition for use according to claim 150, wherein the S1P 1 receptor-associated disorder is an inflammatory disease or disorder.
